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1. 
PROCESSES AND REAGENTS FOR MAKING 
DARYLODONUMISALTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Appli 
cation No. 61/655,860, filed Jun. 5, 2012, which is incorpo 
rated by reference in its entirety. 
TECHNICAL FIELD 
This invention relates to processes and reagents for making 
diaryliodonium salts, which are useful for the preparation of 
fluorinated and radiofluorinated aromatic compounds. 
BACKGROUND 
Diaryliodonium salts are useful as arylating agents for a 
large variety of organic and inorganic nucleophiles. They 
have also been applied in metal-catalyzed cross-coupling 
reactions (Ryan, J. H. and P.J. Stang, Tetrahedron Lett. 1997, 
38, 5061-5064; Zhang, B.-X., et al., Heterocycles 2004, 64, 
199-206: Kang, S.-K., et al., J. Org. Chem. 1996, 61, 4720 
4724; Al-Qahtani, M. H. and V.W. Pike, Perkin 12000, 1033 
1036; Kang, S.-K., et al., Tetrahedron Lett. 1997, 38, 1947 
1950) due to the excellent leaving-group ability of the aryl 
iodide moiety (Okuyama, T., et al., J. Am. Chem. Soc. 1995, 
117, 3360-7). Other than these applications, diaryliodonium 
salts were found to play a role as oxidants for dearomatization 
of phenols (Moriarty, R. M. and O. Prakash, Org. React. (N. 
Y.) 2001, 57, 327–415: Moore, J. D. and P. R. Hanson, 
Chemtracts 2002, 15,74-80; Ciufolini, M.A., et al., Synthesis 
2007, 3759-3772) and as cationic photoinitiators in photo 
chemistry (Toba, Y., J. Photopolym. Sci. Technol. 2003, 16, 
115-118: Crivello, J. V., J. Polym. Sci., Part A: Polym. Chem. 
2009, 47, 866-875: Crivello, J. V., Polym. Prepr. (Am. Chem. 
Soc., Div. Polym. Chem.) 2006, 47, 208-209). 
Diaryliodonium salts are also useful for the synthesis of 
aryl fluorides, for example, in the preparation of F labeled 
radiotracers. Aryl fluorides are structural moieties in natural 
products as well as a number of therapeutically important 
compounds, including pharmaceuticals and positron emis 
sion tomography (PET) tracers. Diaryliodonium salts are par 
ticularly useful for the nucleophilic fluorination of electron 
rich arenes, a class of compounds that is inaccessible using 
conventional nucleophilic fluorination methods. 
For at least these reasons, there is a need to develop new 
routes in diaryliodonium salts, particularly those having a 
broad range of functional groups. This application addresses 
this need and others. 
SUMMARY 
The present application provides, interalia, a process for 
making a compound of Formula I: 
- X: 
comprising treating a compound of Formula II: 
Ar—I II 
with a tetravalent silicon moiety having at least one X group 
bound to Si; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy 
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2 
clo2.2.2]octane)bis(tetrafluoroborate) (SelectFluorTM), (1-fluoro-4-methyl-1,4-diazoniabicyclo[2.2.2]octane)bis 
(tetrafluoroborate) (SelectFluor IITM), or optionally substi 
tuted N-fluoropyridinium tetrafluoroborate; 
wherein: 
each X is, independently, a ligand that is a conjugate base 
of an acid HX, wherein HX has a pKa of less than or equal to 
12; and 
Ar" is optionally substituted arylor heteroaryl, wherein Ar" 
does not have unprotected protic groups. 
The present application further provides a process of con 
Verting the compound of Formula Ito a compound of Formula 
III: 
III 
xe 
o 
A11 NA2 
wherein Aris an optionally substituted aryl or heteroaryl. 
The compound of Formula I can be isolated and then used 
to prepare the compound of Formula III or the two steps can 
be carried out in an efficient one-pot synthesis. 
This process allows the preparation of iodine (III) precur 
sors of Formula I without the use of acidic conditions or the 
use of reagents that must be prepared in acidic media as in 
other synthetic procedures. Acidic conditions are not compat 
ible with substrates featuring acid sensitive moieties or het 
eroatoms that are prone to protonation or oxidation. Hence, 
the current process allows the synthesis of a broad range of 
diaryliodonium salts, which were previously inaccessible. 
For example, the process has been shown to be applicable to 
both electron-rich and electron-deficient arenes and is toler 
ant of molecules featuring acid sensitive moieties and pro 
tected L-amino acid groups. Further, this process is also more 
economical in that less than 2 equivalents of the oxidation 
agent may be utilized to achieve the oxidation, unlike other 
processes which use a high excess of the oxidation agent. 
The present application also provides certain new com 
pounds of Formulas I, II, III, V, VI, or VII. 
DETAILED DESCRIPTION 
The present application provides, interalia, a process for 
making a compound of Formula I: 
-IX): 
comprising treating a compound of Formula II: 
Ar—I II 
with a tetravalent silicon moiety having at least one X group 
bound to Si; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy 
clo2.2.2]octane)bis(tetrafluoroborate), (1-fluoro-4-methyl 
1,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate), or 
optionally substituted N-fluoropyridinium tetrafluoroborate; 
wherein: 
each X is, independently, a ligand that is a conjugate base 
of an acid HX, wherein HX has a pKa of less than or equal to 
12; and 
Ar' is optionally substituted aryl or heteroaryl. 
In some embodiments, Ar" does not have any iodo groups (e.g., Ar"—I has only the single iodo group). 
US 9.278,959 B2 
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In some embodiments, Ar' is optionally substituted aryl or 
heteroaryl, wherein Ar" does not have unprotected protic 
groups. As used herein, protic groups' means groups having 
a hydrogen atom directly attached to an oxygen, nitrogen or 
Sulfur atom (non-limiting examples of these groups include 
alcohols, primary and secondary amines, carbamates, ureas, 
amides, Sulfonic acids, thiols, hydrazines, hydrazides, and 
semicarbazides). 
As described above, the current process allows the synthe 
sis of a broad range of diaryliodonium salts, including both 
electron-rich and electron-deficient arenes and is tolerant of 
molecules featuring acid sensitive moieties and protected 
L-amino acid groups. 
Without wishing to be bound by any theory, the process is 
believed to operate by the process shown in the example 
below. It is thought that the highly activated I(III) intermedi 
ate aryl-IF+, formed from two-electron oxidation of an aryl 
iodide by F-TEDA-BF, is sufficiently Lewis acidic to 
remove a fluoride from BF to form the aryl-IF trifluo 
roborane complex. Aryl-IF reacts subsequently with TMS-X 
to give 1a and TMSF, while boron trifluoride is coordinated 
by the free amine of reduced Selectfluor to form the Zwitte 
rionic adduct, which is able to exchange fluoride with excess 
TMS-X (e.g., TMSOAc). The aryl-IF compound undergoes 
a fast ligand exchange process with X—. The premixed 
TMSOAc therefore converted aryl-IF to corresponding Arl 
(OAc) immediately upon formation of ArF. 
10 
15 
25 
4 
bamyl, di(C. alkyl)carbamyl, carboxy, amino, Ce alky 
lamino, di-C alkylamino, Calkylcarbonyl, Calkoxy 
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino, 
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul 
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino, 
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony 
lamino, aminocarbonylamino, Ce alkylaminocarbony 
lamino, and di(Calkyl)aminocarbonylamino; wherein said 
C- alkyl, Cao cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl are each optionally substi 
tuted by one or more groups selected from halo, cyano, nitro, 
C- alkyl, Ce haloalkyl, C2-alkenyl, C2-alkynyl, C 
alkoxy, hydroxy, Calkoxy, Chaloalkoxy, Calkylthio. 
C. alkylsulfinyl, Ce alkylsulfonyl, carbamyl, C. alkyl 
carbamyl, di(Calkyl)carbamyl, carboxy, amino, Calky 
lamino, di-C alkylamino, Calkylcarbonyl, Calkoxy 
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino, 
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul 
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino, 
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony 
lamino, aminocarbonylamino, C alkylaminocarbony 
lamino, di(C. alkyl)aminocarbonylamino, and Co 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl. 
C 
r C (BF4 BF4- r ce C S 
2BF4- r N N BF4- (S 
N-- 
N TMSF hio 
N N-- F1 W 
his F 
IN a ) Fi II. B F1 Y. 
F ? \ I-F F-I-F AcO-I-OAC 
7 TMSOAC 
-e- - - 
TMSF 
OMe OMe OMe OMe 
In some embodiments, the process is carried out in the 
absence of added acid (e.g., protic acid). 
In some embodiments, the process utilizes (1-chlorom 
ethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)bis(tet 
rafluoroborate). 
In some embodiments, the process utilizes (1-fluoro-4- 
methyl-1,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluorobo 
rate). 
In some embodiments, the process utilizes N-fluoropyri 
dinium tetrafluoroborate, wherein the pyridine ring is option 
ally substituted by 1, 2, 3, 4, or 5 groups independently 
selected from halo, cyano, nitro, Ce alkyl, Ce haloalkyl, 
Coalkenyl, C2-alkynyl, Co cycloalkyl, Co cycloalkyl 
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
C-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl, 
hydroxy, C. alkoxy, C- haloalkoxy, Co alkylthio. C 
alkylsulfinyl, Ce alkylsulfonyl, carbamyl, Ce alkylcar 
50 
55 
60 
65 
In some embodiments, the process utilizes N-fluoropyri 
dinium tetrafluoroborate, wherein the pyridine ring is option 
ally substituted by 1, 2, 3, 4, or 5 groups independently 
selected halo groups. 
In some embodiments, the process utilizes N-fluoropyri 
dinium tetrafluoroborate, wherein the pyridine ring is option 
ally substituted by 1, 2, 3, 4, or 5 groups independently 
selected halo groups. 
In some embodiments, the process utilizes N-fluoro-2,3,4, 
5,6-pentachloropyridinium tetrafluoroborate. 
In some embodiments, the process utilizes less than 2 
equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo 
2.2.2]octane)bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4- 
diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate), O 
optionally substituted N-fluoropyridinium tetrafluoroborate 
for 1 equivalent of the compound of Formula II. In some 
embodiments, the process utilizes less than 1.5 equivalents of 
US 9.278,959 B2 
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(1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane) 
bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4-diazoniabicy 
clo2.2.2]octane)bis(tetrafluoroborate), or optionally substi 
tuted N-fluoropyridinium tetrafluoroborate for 1 equivalent 
of the compound of Formula II. 
In some embodiments, each X is, independently, a ligand 
that is a conjugate base of an acid HX, wherein HX has a pKa 
of less than or equal to 5. 
In some embodiments, X can be chosen from halide, aryl 
carboxylate, alkyl carboxylate, phosphate, phosphonate, 
phosphonite, azide, thiocyanate, cyanate, phenoxide, triflate, 
thiolates, and stabilized enolates. 
In some embodiments, X is O(C=O)CH. 
In some embodiments, the tetravalent silicon moiety is 
(R'),Si X, (R').Si (X), R'Si (X), and Si(X): 
wherein each R' is, independently, C, alkyl or aryl. 
In some embodiments, the tetravalent silicon moiety is (R'),Si X, wherein each R' is, independently, C-12 alkylor 
aryl. 
In some embodiments, each R' is, independently, C-12 
alkyl. 
In some embodiments, each R' is, independently, Ca 
alkyl. 
In some embodiments, each R' is independently, methyl. 
In some embodiments, (R'),Si X is (CH),Si X. 
In some embodiments, (R')Si X is (CH)Si-O 
(C=O)CH. 
At various points, the process utilizes protecting groups. 
Appropriate protecting groups for various functional groups 
include, but are not limited to the protecting groups delin 
eated in Wuts and Greene, Protective Groups in Organic 
Synthesis, 4th ed., John Wiley & Sons: New Jersey, which is 
incorporated herein by reference in its entirety. For example, 
protecting groups for amines include, but are not limited to, 
t-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), 2.2.2- 
trichloroethoxycarbonyl (Troc), 2-(4-trifluoromethylphenyl 
Sulfonyl)ethoxycarbonyl (Tsc), 1-adamantyloxycarbonyl 
(Adoc), 2-adamantylcarbonyl (2-Adoc), 2,4-dimethylpent-3- 
yloxycarbonyl (Doc), cyclohexyloxycarbonyl (Hoc), 1,1- 
dimethyl-2.2.2-trichloroethoxycarbonyl (TcPOC), vinyl, 
2-chloroethyl 2-phenylsulfonylethyl, allyl, benzyl, 2-ni 
trobenzyl, 4-nitrobenzyl, diphenyl-4-pyridylmethyl, N',N'- 
dimethylhydrazinyl, methoxymethyl, t-butoxymethyl 
(Bum), benzyloxymethyl (BOM), or 2-tetrahydropyranyl 
(THP). 
Carboxylic acids can be protected as their alkyl, allyl, or 
benzyl esters, among other groups. 
Alcohols can be protected as esters, such as acetyl, ben 
Zoyl, or pivaloyl, or as ethers. Examples of ether protecting 
groups for alcohols include, but are not limited to alkyl, allyl, 
benzyl, methoxymethyl (MOM), t-butoxymethyl, tetrahy 
dropyranyl (THP), p-methoxybenzyle (PMB), trity1, and 
methoxyethoxymethyl (MEM). 
In some embodiments, the protecting groups are acid labile 
protecting groups. 
In some embodiments, the protecting groups are base labile 
protecting groups. 
In some embodiments, the protecting group are acid labile 
protecting groups, which can be easily be removed at the end 
of all synthetic steps under acidic deprotection conditions. 
In Some embodiments, the process utilizes 2 equivalents or 
more of the tetravalent silicon moiety for 1 equivalent of the 
compound of Formula II. As used herein, the equivalents are 
per X group bound to the Siatom of the tetravalent silicon 
moiety (e.g., when 2X groups are bound to the Siatom, then 
only 1 equivalent or more of the tetravalent silicon moiety are 
needed for 1 equivalent of the compound of Formula II). In 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
Some embodiments, the process utilizes 2.5 equivalents to 3 
equivalents of the tetravalent silicon moiety for 1 equivalent 
of the compound of Formula II. In some embodiments, the 
process utilizes 2 equivalents or more of (R'),Si X for 1 
equivalent of the compound of Formula II. In some embodi 
ments, the process utilizes 2.5 equivalents to 3 equivalents of (R')Si X for 1 equivalent of the compound of Formula II. 
In some embodiments, the processes comprises treating a 
compound of Formula II with (CH),Si O(C=O)CH; and (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane) 
bis(tetrafluoroborate). In some embodiments, the processes 
comprises treating a compound of Formula II with 2.5 equiva 
lents to 3 equivalents of (CH)-Si-O(C=O)CH; and less 
than 1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazo 
niabicyclo[2.2.2]octane)bis(tetrafluoroborate). 
In some embodiments: 
Ar' is aryl or heteroaryl, which is optionally substituted by 
one or more groups independently selected from halo, cyano, 
nitro, C-alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, 
C- alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl, 
C. heterocycloalkyl, C. heterocycloalkyl-C-alkyl, 
Co-14 aryl, C-14 aryl-C-4-alkyl, C-14 heteroaryl, C-14 het 
eroaryl-C-alkyl, - S(=O)R. S(=O).R", S(=O). 
NRSR, C(=O)R, C(=O)NR'R'', OC(=O)R", 
OC(=O)NR'R'', NRC(=O)R", NR“C(=O)CR, 
NRC(=O)NRSNR, NRS(—O).R., NR“S(—O), 
NRSR, C( NR)NRSR, NRC( NR)NRSR, OC, 
–SR, S(=O),OR, C(=O)CR', and NR&R"; 
wherein said C. alkyl, Ce haloalkyl, C2-alkenyl, C2 
alkynyl, Calkoxy, C-acycloalkyl, C-acycloalkyl-Ca 
alkyl, C. heterocycloalkyl, C. heterocycloalkyl-Ca 
alkyl, Caryl, Caryl-C-alkyl, C. heteroaryl, and 
C. heteroaryl-C-alkyl are each optionally substituted by 
one or more independently selected R groups; 
each R is independently selected from H. C. alkyl, CN, 
Calkoxy, or C(O)C alkyl; 
each R" is independently selected from H. C. alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Coheteroaryl, wherein said C. alkyl, Chaloalkyl, C 
alkenyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl 
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
Ca-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl, 
and Co. heteroaryl-C-alkyl are each optionally Substi 
tuted by one or more independently selected R groups; 
each R is independently selected from C, alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C2-alkynyl, aryl, Cao cycloalkyl, Cso cycloalkyl 
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
C-alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, 
and Co. heteroaryl-C-alkyl are each optionally Substi 
tuted by one or more independently selected R groups: 
each R is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2- alkenyl, C2- alkynyl, aryl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
US 9.278,959 B2 
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each R" is independently selected from a protecting group, 
C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-C- 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C. haloalkyl, C- alkenyl, C- alkynyl, aryl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally substituted by one or more indepen 
dently selected R groups; 
each R', R and R' is independently selected from a pro 
tecting group, Ce alkyl, Ce haloalkyl, Calkenyl, C 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C 
alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-C- 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, RandR', taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR, taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR, taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR', taken together with the nitrogen 
atom to which they are attached, form a heterocycloalkyl or 
heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C. alkyl, C- haloalkyl, C- haloalkyl, C2-alkenyl, C2 
alkynyl, Calkoxy, Co cycloalkyl, Co cycloalkyl-C- 
alkyl, Co heterocycloalkyl, C7-o heterocycloalkyl-C- 
alkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10 
heteroaryl-C-alkyl, S(=O)R', S(=O).R', 
S(=O)NR3'R'', C(=O)R'', C(=O)NR'R'', 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
8 
OC(=O)R', OC(=O)NR3'R'', NRC(=O)R', 
NRC(O)OR, NRC(O)NR&NR'', NR'S (—O).R', NR'S(=O)NR's 'R'', C(-NR)NR'R'', 
NRC(—NR)NR&R'', OR', SR', S(–O).OR', 
—C(=O)CR', and - NR3'R'': wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co alkoxy, Cao 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R' is independently selected from H. C. alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, Calk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and 
Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R groups; 
each R' is independently selected from C, alkyl, C 
haloalkyl, Calkenyl, C2-alkynyl, Co cycloalkyl, Co 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and 
Coheteroaryl-C-alkyl are each optionally substituted by 
one or more independently selected R groups; 
each R' is independently selected from a protecting group, 
C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R groups; 
each R" is independently selected from a protecting 
group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, 
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
Rgroups; 
each R' is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
Rgroups; 
each R is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
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cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
Rgroups; 
each R', R3 and R' is independently selected from a 
protecting group, C-alkyl, Chaloalkyl, C2-alkenyl, C2 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C 
alkyl, Ce haloalkyl, C- alkenyl, C- alkynyl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
Rgroups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
Rgroups; 
or alternatively, R'' and R', taken together with the nitro 
gen atom to which they are attached, form a heterocycloalkyl 
or heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C. alkyl, C- haloalkyl, C- haloalkyl, C2-alkenyl, C2 
alkynyl, Calkoxy, Cao cycloalkyl, Co cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-C- 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Coheteroaryl, Co 
heteroaryl-C-alkyl, S(=O)R’, S(=O)R’, 
S(=O)NR8R, C(=O)R’?, C(=O)NR8R, 
OC(=O)R’, OC(=O)NR&R', NR°C(=O)R’, 
NRC(O)OR, NRC(O)NR3°NR, NRS (—O).R.?, NR'2S(O)NR3°R2, C( NR)NR3°Rh2, 
NRC( NR)NR8R, OR, SR', S(O).OR, 
—C(=O)CR?, and - NRSR’; wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Calkoxy, Cao 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R' groups; 
each R' is independently selected from H. C. alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-C- 
alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, and 
Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R' groups; 
each R’ is independently selected from C, alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
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heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and 
Coheteroaryl-C-alkyl are each optionally substituted by 
one or more independently selected R'groups; 
each R is independently selected from a protecting group, 
C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R" groups: 
each R is independently selected from a protecting 
group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, 
Co cycloalkyl, Co cycloalkyl-C-alkyl, Coheterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R" groups: 
each R’ is independently selected from a protecting group, 
C-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R“groups: 
each R is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C,e-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R" groups: 
each R', R and R' is independently selected from a 
protecting group, Calkyl, Chaloalkyl, Calkenyl, C 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Cao aryl-C-alkyl, Coheteroaryl, wherein said C. 
alkyl, Ce haloalkyl, C2- alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, RandR', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R“groups: 
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or alternatively, RandR', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R“groups: 
or alternatively, RandR, taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R“groups: 
or alternatively, RandR', taken together with the nitro 
gen atom to which they are attached, form a heterocycloalkyl 
or heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C, alkyl, Chaloalkyl, Ce alkyl-NR'—C, alkylene, 
Coalkyl-O-C-alkylene, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Coheteroaryl, Coheteroaryl-Ca-alkyl, 
hydroxy, C. alkoxy, C- haloalkoxy, Co alkylthio. C 
alkylsulfinyl, Ce alkylsulfonyl, carbamyl, Ce alkylcar 
bamyl, di(C. alkyl)carbamyl, carboxy, amino, C alky 
lamino, di-C alkylamino, Ce alkylcarbonyl, Calkoxy 
carbonyl, C. alkylcarbonyloxy, C alkylcarbonylamino, 
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul 
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino, 
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony 
lamino, aminocarbonylamino, Ce alkylaminocarbony 
lamino, and di(Calkyl)aminocarbonylamino; wherein said 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, C 
alkoxy, alkylene, C alkyl-O-C alkylene, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-C- 
alkyl are each optionally Substituted by one or more groups 
selected from halo, cyano, nitro, C alkyl, Chaloalkyl, 
C2-alkenyl, C2-alkynyl, C-calkoxy, hydroxy, Calkoxy, 
Chaloalkoxy, Calkylthio, Calkylsulfinyl, Ce alkyl 
Sulfonyl, carbamyl, Ce alkylcarbamyl, di(C. alkyl)car 
bamyl, carboxy, amino, Calkylamino, di-C alkylamino, 
C. alkylcarbonyl, Calkoxycarbonyl, C. alkylcarbony 
loxy, Ce alkylcarbonylamino, Ce alkylsulfonylamino, 
aminosulfonyl, C. alkylaminosulfonyl, di(C. alkyl)ami 
nosulfonyl, aminosulfonylamino, Ce alkylaminosulfony 
lamino, di(C. alkyl)aminosulfonylamino, aminocarbony 
lamino, C1-6 alkylaminocarbonylamino, alkyl) 
aminocarbonylamino, Cao cycloalkyl, Cso cycloalkyl 
C -alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
C-4-alkyl, Co-lo aryl, Co-o C1-10 heteroaryl and Co het 
eroaryl-C alkyl; and 
each R" is independently selected from Hand C, alkyl. 
In one embodiments of the aformentioned embodiment, it 
is provided that each hydrogen atom in which is directly 
attached to a nitrogen atom, Sulfur atom, or oxygen atom in 
any of the aforementioned groups (e.g., heteroaryl, heterocy 
cloalkyl, C. alkyl-NR" C- alkylene, hydroxy, car 
bamyl, carboxy, amino, C alkylamino, Calkylsulfony 
lamino, aminosulfonyl, C. alkylaminosulfonyl, 
aminosulfonylamino, Calkylaminosulfonylamino, di(C. 
alkyl)aminosulfonylamino, aminocarbonylamino, Calky 
laminocarbonylamino, and di(C. alkyl)aminocarbony 
lamino) is replaced by a protecting group. 
Starting materials of Formula II can be obtained by react 
ing the aryl or heteroaryl substrate with a N-iodosuccinamide 
(NIS) in an appropriate solvent such as dry acetonitrile to give 
a compound of Formula II. Protecting groups can added if 
necessary as described in Wuts and Greene, Protective 
Groups in Organic Synthesis, 4th ed., John Wiley & Sons: 
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New Jersey, which is incorporated herein by reference in its 
entirety. For example, amine groups can be protected by 
reacting di-tert-butyl dicarbonate (BOC anhydride in the 
presence of a tertiary amine (e.g., 4-dimethylpyridine and 
triethylamine) to form a BOC (tert-butylcarbonyl) protected 
amine 
In some embodiments, the present application provides a 
process of converting the compound of Formula I to a com 
pound of Formula III: 
III 
xe 
o 
A11 NA2 
wherein Ari is an optionally substituted aryl or heteroaryl. 
In some embodiments, the conversion of the compound of 
Formula I to a compound of Formula III is done in the same 
pot as the reaction of the compound of Formula II to form the 
compound of Formula I. 
In some embodiments, the converting comprises reacting 
the compound of Formula I with a compound of Formula IV: 
wherein M' is aborate, stannane, silane, or zinc moiety. 
In some embodiments, M' is Sn(R), Si(R), B(OR), or 
BCX),M; wherein: 
each R is, independently, C alkyl: 
each R' is, independently, Ce alkyl, 
each R is, independently, OH or Calkoxy; or 
two R groups, taken together with the oxygen atoms to 
which they are attached and the boron atom to which the 
oxygen atoms are attached, form a 5- to 6-membered hetero 
cyclic ring, which is optionally Substituted with 1, 2, 3, or 4 
C. alkyl groups; 
each X is, independently, halo; and 
M° is a counterion. 
In some embodiments, the Zinc moiety is an Zinc halide 
(Zn-halo). In some embodiments, the arylzinc halide is Zinc 
chloride. 
In some embodiments, the compound of Formula IV is 
ArBF.M. 
In some embodiments, the compound of Formula IV is 
Ar’BFK. 
In some embodiments, the process is carried out in the 
presence of a catalyst. 
In some embodiments, the catalyst is trimethylsilyl trifluo 
rOacetate. 
The use of ArBFM is preferred over the other reagents. 
Compared to organostannanes, organoboranes are relatively 
straightforward to handle and are quite reactive toward I(III) 
compounds. However, organoboranes themselves are limited 
by the inherent characteristics of the in situ hydroboration 
reaction used to create them. They also suffer from high 
sensitivity to air and poor functional-group compatibility in 
Some cases. In contrast, aryltrifluoroborates are stable, crys 
talline compounds that have been shown to overcome these 
limitations. Organotrifluoroborates can be easily prepared 
from inexpensive materials. They are stable to air and mois 
ture, features that allow shipping and storage of these 
reagents for long periods of time without noticeable degra 
dation. Their versatility and stability has made them excellent 
reagents in many organic reactions. Further, trifluoroborates 
have the ability to resist chemical oxidation. This feature 
offers aryltrifluoroborates a unique opportunity to preserve 
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the carbon-boron bond during the oxidation of remote func 
tionality within the same molecule. Organoboron compounds 
are generally incompatible with oxidants, which readily 
cleave the labile carbon-boron bond. Organotrifluoroborates 
can be utilized to overcome this limitation in an important 
way; since the organometallic reagent needs to be stable to 
excess Selectfluor reagent that is present in one-pot synthetic 
approach. The oxidative strength of Selectfluor reagent is 
well tolerated by aryltrifluoroborates; they are unffected by 
residual Selectfluor. 
In one embodiment (a), Ar' and Ari are each, indepen 
dently, aryl or heteroaryl, which is optionally substituted by 
one or more groups independently selected from halo, cyano, 
nitro, Calkyl, Chaloalkyl, Calkenyl, C2-alkynyl, 
C. alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl, 
C. heterocycloalkyl, C. heterocycloalkyl-C-alkyl, 
Co-14 aryl, C-14 aryl-C-4-alkyl, C-14 heteroaryl, C-14 het 
eroaryl-C-alkyl, —S(=O)R’, S(=O).R. S(=O) 
NRSR, C(=O)NRSR, OC(=O)R, OC(=O) 
NR&R", NR“C(=O)R", NRC(=O)CR, NR“C (=O)NRSNR, NRS(—O).R, NRS(=O)NRSR, 
C(-NR)NR'R'', NR“C(—NR)NR'R'', OC, SR, 
—S(=O)OR, C(=O)CR, and NRSR'; wherein said 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, C 
alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl, C-14 
heterocycloalkyl, C-a heterocycloalkyl-C-alkyl, C 
aryl, C-14 aryl-Ca-alkyl, C-14 heteroaryl, and C-14 het 
eroaryl-C-alkyl are each optionally substituted by one or 
more independently selected R groups; 
each R" is independently selected from H. C. alkyl, CN, 
Calkoxy, or C(O)C alkyl; 
each R" is independently selected from H. C. alkyl, C. 
haloalkyl, Calkenyl, C-alkynyl, aryl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Coheteroaryl, wherein said C. alkyl, Chaloalkyl, C 
alkenyl, C2-alkynyl, Cso cycloalkyl, Cao cycloalkyl 
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
C-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl, 
and Co heteroaryl-C-alkyl are each optionally substi 
tuted by one or more independently selected R groups; 
each R is independently selected from C, alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C- alkynyl, aryl, Co cycloalkyl, Co cycloalkyl 
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl 
C-alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, 
and Co. heteroaryl-C-alkyl are each optionally Substi 
tuted by one or more independently selected R groups; 
each R is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R" is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-C-alkyl, heterocycloalkyl, 
Coheterocycloalkyl-Ca-alkyl, Co-o aryl, Co-oaryl-Ca 
alkyl, Co heteroaryl, wherein said C. alkyl, C. 
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haloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cao cycloalkyl, 
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R groups; 
each R is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C- haloalkyl, C2- alkenyl, C2- alkynyl, aryl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R is independently selected from a protecting group, 
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
C. haloalkyl, C- alkenyl, C- alkynyl, aryl, Co 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R', R and R' is independently selected from a pro 
tecting group, Ce alkyl, Ce haloalkyl, Calkenyl, C 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-Ca-alkyl, Co 
aryl, Co aryl-C-alkyl, Coheteroaryl, wherein said C. 
alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, RandR', taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR', taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR, taken together with the atoms to 
which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, RandR', taken together with the nitrogen 
atom to which they are attached, form a heterocycloalkyl or 
heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C- alkyl, Chaloalkyl, C- haloalkyl, C2-alkenyl, C2 
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10 
heteroaryl-C-alkyl, S(=O)R', S(=O).R', 
S(=O)NR3'R'', C(=O)R'', C(=O)NR'R'', OC (=O)R'', OC(=O)NR&R'', NRS(=O)NR&R'', 
C( NR)NR3'R'', NRC( NR)NR&R'', OR, 
SR', S(–O),OR', C(=O)CR?, and NR&R'; 
wherein said C. alkyl, Ce haloalkyl, C2-alkenyl, C2 
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca 
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alkyl, Co heterocycloalkyl, Co heterocycloalkyl-C- 
alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, and 
Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R groups; 
each R' is independently selected from H. C. alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-C- 
alkyl, Cao aryl, Co-o aryl-Ca-alkyl, Coheteroaryl, and 
Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R groups; 
each R' is independently selected from C. alkyl, C 
haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl-C- 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-C- 
alkyl, Cao aryl, Co-o aryl-Ca-alkyl, Coheteroaryl, and 
Coheteroaryl-C-alkyl are each optionally substituted by 
one or more independently selected R groups; 
each R' is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co cycloalkyl, 
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
Rgroups; 
each R' is independently selected from a protecting 
group, Ce alkyl, Chaloalkyl, Calkenyl, C-alkynyl, 
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
Rgroups; 
each R' is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, Calkenyl, C- alkynyl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R groups; 
each R is independently selected from a protecting group, 
C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
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Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R groups; 
each R', R' and R' is independently selected from a 
protecting group, Calkyl, Chaloalkyl, Calkenyl, C 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Co aryl-C-alkyl, Coheteroaryl, wherein said C. 
alkyl, Ce haloalkyl, C2- alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
Rgroups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R groups; 
or alternatively, R'' and R', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
Rgroups; 
or alternatively, RandR'', taken together with the nitro 
gen atom to which they are attached, form a heterocycloalkyl 
or heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C. alkyl, Chaloalkyl, Chaloalkyl, Calkenyl, C 
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10 
heteroaryl-C-alkyl, S(=O)R’, S(=O)R’, 
S(=O)NR&R', C(=O)R’, C(=O)NR&R', 
OC(=O)R’, OC(=O)NR&R', NR°C(=O)R’, 
NR**C(O)OR2, NRC(O)NR3°NR'2, NR'S (—O).R, NRS(O)NR8R, C( NR)NR8R, 
NRC( NR)NR3°R2, OR2, SR2, S(O) OR2, 
—C(=O)CR', and - NR'R'': wherein said C, alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co alkoxy, Cao 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
each R' is independently selected from H, C, alkyl, C. 
haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, Calk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and 
Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R' groups; 
each R” is independently selected from C, alkyl, C. 
haloalkyl, Calkenyl, C2-alkynyl, Co cycloalkyl, Co 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-C-alkyl, Co aryl, Co aryl-C-alkyl, Co 
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk 
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca 
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca 
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and 
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Coheteroaryl-C-alkyl are each optionally Substituted by 
one or more independently selected R' groups; 
each Risindependently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, Calkenyl, C- alkynyl, Co cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R“groups: 
each R" is independently selected from a protecting 
group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, 
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R“groups: 
each R’ is independently selected from a protecting group, 
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co cycloalkyl, 
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R“groups: 
each R is independently selected from a protecting group, 
C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o 
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl, 
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, 
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co 
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl, 
Co heteroaryl, and Co. heteroaryl-C-alkyl are each 
optionally substituted by one or more independently selected 
R“groups: 
each R', R3 and R' is independently selected from a 
protecting group, C-alkyl, Chaloalkyl, C2-alkenyl, C2 
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C 
alkyl, Ce haloalkyl, C- alkenyl, C- alkynyl, Co 
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy 
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co 
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca 
alkyl are each optionally Substituted by one or more indepen 
dently selected R groups; 
or alternatively, RandR', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R" groups: 
or alternatively, RandR', taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R“groups: 
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or alternatively, RandR, taken together with the atoms 
to which they are attached, form a heterocycloalkyl or het 
eroaryl ring, which is optionally substituted by one or more 
R“groups: 
or alternatively, R° and R', taken together with the nitro 
gen atom to which they are attached, form a heterocycloalkyl 
or heteroaryl ring, which is optionally substituted by one or 
more R groups; 
each R is independently selected from halo, cyano, nitro, 
C. alkyl, C. haloalkyl, C- alkyl-NR" C. alkylene, 
C1-alkyl-O-C alkylene, C2-alkenyl, C2-alkynyl, Cso 
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy 
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co 
aryl-C-alkyl, Coheteroaryl, Coheteroaryl-C-alkyl, 
hydroxy, Calkoxy, Co haloalkoxy, Co alkylthio. C 
alkylsulfinyl, C. alkylsulfonyl, carbamyl, C. alkylcar 
bamyl, di(C. alkyl)carbamyl, carboxy, amino, Ce alky 
lamino, di-C alkylamino, Ce alkylcarbonyl, Calkoxy 
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino, 
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul 
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino, 
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony 
lamino, aminocarbonylamino, C alkylaminocarbony 
lamino, and di(Calkyl)aminocarbonylamino; wherein said 
C- alkyl, Ce haloalkyl, C2-alkenyl, C2-alkynyl, C 
alkoxy, C. alkyl-NR'—C. alkylene, C. alkyl-O-C- 
alkylene, Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co 
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co 
aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and Co het 
eroaryl-C-alkyl are each optionally substituted by one or 
more groups selected from halo, cyano, nitro, Ce alkyl, C. 
haloalkyl, Calkenyl, C- alkynyl, Calkoxy, hydroxy, 
Calkoxy, Chaloalkoxy, C alkylthio, Calkylsulfi 
nyl, Calkylsulfonyl, carbamyl, Calkylcarbamyl, di(C. 
alkyl)carbamyl, carboxy, amino, C alkylamino, di-C 
alkylamino, Ce alkylcarbonyl, Ce alkoxycarbonyl, C. 
alkylcarbonyloxy, Calkylcarbonylamino, Calkylsulfo 
nylamino, aminosulfonyl, Ce alkylaminosulfonyl, di(C. 
alkyl)aminosulfonyl, aminosulfonylamino, Ce alkylamino 
Sulfonylamino, di(C. alkyl)aminosulfonylamino, ami 
nocarbonylamino, Ce alkylaminocarbonylamino, di(C. 
alkyl)aminocarbonylamino, Co cycloalkyl, Co 
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero 
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co 
heteroaryland Coheteroaryl-C alkyl; and 
each R" is independently selected from Hand C alkyl: 
provided that each hydrogen atom in which is directly 
attached to a nitrogen atom, Sulfur atom, or oxygen atom in 
any of the aforementioned groups (e.g., heteroaryl, heterocy 
cloalkyl, C. alkyl-NR" C. alkylene, hydroxy, car 
bamyl, carboxy, amino, Ce alkylamino, Calkylsulfony 
lamino, aminosulfonyl, Ce alkylaminosulfonyl, 
aminosulfonylamino, Calkylaminosulfonylamino, di(C. 
alkyl)aminosulfonylamino, aminocarbonylamino, Calky 
laminocarbonylamino, and di(C. alkyl)aminocarbony 
lamino) is replaced by a protecting group. 
In some embodiments, optionally Substituted means Sub 
stituted one or more groups independently selected fromhalo, 
cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, 
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, 
aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, alkoxy, 
haloalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, car 
bamyl, alkylcarbamyl, carbamyl, carboxy, amino, alky 
lamino, di. alkylamino, alkylcarbonyl, alkoxycarbonyl, 
H-carbonyloxy, H-carbonylamino, H-Sulfonylamino, amino 
Sulfonyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, ami 
nosulfonylamino, alkylaminosulfonylamino, di(alkyl)ami 
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nosulfonylamino, aminocarbonylamino, 
alkylaminocarbonylamino, dialkyl)aminocarbonylamino, 
hydrazine, hydrazines, hydrazides, and semicarbazides; 
wherein each group can be further optionally substituted by 
one or more groups independently selected from the afore 
mentioned groups. In some embodiments, multiple layers of 
substitution are permitted. 
In some embodiments, Ar" and Ari do not comprise an iodo 
group. 
In some embodiments, Ar' is defined as in embodiment (a). 
In some embodiments, Aris defined as in embodiment (a). 
In some embodiments, Ari is aryl substituted by 1, 2, 3, 4, 
or 5 Calkoxy groups. 
In some embodiments, Ar’ is aryl substituted by 1, 2, 3, 4, 
or 5 methoxy groups. 
In some embodiments, Ar is aryl substituted by 1 or 2C 
alkoxy groups. 
In some embodiments, Ari is aryl substituted by 1 or 2 
methoxy groups. 
In some embodiments, Ar’ is aryl substituted by 1C 
alkoxy group. 
In some embodiments, Ari is aryl substituted by 1 methoxy 
group. 
In some embodiments, Ar is phenyl substituted by 1,2,3, 
4, or 5 Calkoxy groups. 
In some embodiments, Ar is phenyl substituted by 1,2,3, 
4, or 5 methoxy groups. 
In some embodiments, Ar is phenyl substituted by 1 or 2 
Calkoxy groups. 
In some embodiments, Ar is phenyl substituted by 1 or 2 
methoxy groups. 
In some embodiments, Ari is phenyl substituted by 1 C. 
alkoxy group. 
In some embodiments, Ari is phenyl substituted by 1 meth 
OXy group. 
In some embodiments, Ar is p-methoxyphenyl. 
In some embodiments, Ar is 3,4-dimethoxyphenyl. 
In some embodiments, Aris Formula (I): 
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wherein: 
R" is hydrogen or a substituent having a Hammett o, value 
of less than Zero; and 
R,R,R,R,R, and Rare independently selected from 
the group consisting of H. CF. OCF, CN, hydroxyl, amino, 
aminoalkyl, (CH)N(CH2), —SR, SOR, halo, S.O.R. 
(CH), OR, C(=O)NR'R', SONRR, NRSOR, 
COOR, NRC(=O)R, NRC(=O)NR', SO.R., (CH),C 
(=O)NR'R'', (CH), SONR'R'', (CH)NRSO.R. (CH), 
COOR, (CH), NRC(=O)R’, (CH), NRC(=O)NR, 
alkoxy, substituted or unsubstituted alkyl, substituted or 
unsubstituted alkenyl, substituted or unsubstituted alkynyl, 
substituted or unsubstituted cycloalkyl, substituted or unsub 
stituted heterocycloalkyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heteroaryl, and (L)-Z, or one or 
more of RandR, RandR', and RandR come together to 
form a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl 
ring System; 
each m, n, and pare independently an integer from 0 to 10; 
each R and Rare independently chosen from H, substi 
tuted or unsubstituted alkyl, substituted or unsubstituted alk 
enyl, substituted or unsubstituted alkynyl, substituted or 
unsubstituted cycloalkyl, substituted or unsubstituted hetero 
cycloalkyl, substituted or unsubstituted aryl, and substituted 
or unsubstituted heteroaryl; 
L is a linker; and 
Z is a Solid Support. 
The aryl rings on the cyclophane moiety can be substituted 
or unsubstituted. In some embodiments, R' is selected from 
the group consisting of —(C-Co)alkyl, —(C-Co)ha 
loalkyl, (C-C)alkenyl, (C-C)alkynyl, —O—(C-C) 
alkyl, -C(O)—O—(C-Co.)alkyl, aryl, and heteroaryl. For 
example, R' can be -O-(C-Co)alkyl (e.g., OCH). In some 
embodiments, R is —O (C-C)alkyl (e.g., OCH). For 
example, a compound of Formula (1) can be chosen from: 
R1 
In some embodiments, one or more of R-R is (L)-Z. L 
and Z can be covalently or noncovalently bound to one 
another. 
In some embodiments, Ar’ is any of the cyclophanes in US 
2011/0190505, which is incorporated herein by reference in 
its entirety. 
In some embodiments, Ar' is defined as in embodiment (a): 
and Ar is one of the specific embodiments above. 
In some embodiments, the present application provides a 
compound of Formula I or III as defined herein, wherein Ar" 
comprises at least one acid-labile protecting group or acid 
sensitive group. In some embodiments, “acid-labile' or 
“acid-sensitive” means not stable to or protonated by 1 N 
hydrochloric acid. 
In some embodiments, the process further comprises Sub jecting the compound of Formula III to ion-exchange in order 
to form a compound of Formula V: 
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e 
o 
A11 NA2 
wherein Y is a counterion that is different than X. 
In some embodiments, Y is a weakly coordinating anion 
(i.e., an anion that coordinates only weakly with iodine). For 
example, Y can be the conjugate base of a strong acid, for 
example, any anion for which the pKa of the conjugate acid 
(H Y) is less than about 1. For example, Y can be triflate, 
mesylate, nonaflate, hexaflate, toluene Sulfonate (tosylate), 
nitrophenyl Sulfonate (nosylate), bromophenyl Sulfonate 
(brosylate), perfluoroalkyl Sulfonate (e.g., perfluoro Co 
alkylsulfonate), tetraphenylborate, hexafluorophosphate, tri 
fluoroacetate, perfluoroalkylcarboxylate, tetrafluoroborate, 
perchlorate, hexafluorostibate, hexachlorostibate, chloride, 
bromide, or iodide. In some embodiments, a slightly more 
basic leaving group Such as acetate or benzoate may be used. 
In some embodiments, the ion-exchange comprises treat 
ing the compound of Formula III with an aqueous Solution of 
hexafluorophosphate ion, wherein Y is PF -. 
In some embodiments, the ion-exchange comprises treat 
ing the compound of Formula III with an aqueous Solution of 
sodium hexafluorophosphate ion, wherein Y is PF -. 
The present application further provides a process of form 
ing a compound of Formula III: 
III 
xe 
o 
A11 NA2 
comprising: 
(a) treating a compound of Formula II: 
Ar—I II 
with more than 2 equivalents of (R'),Si X; and less than 2 
equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo 
2.2.2]octane)bis(tetrafluoroborate) or (1-fluoro-4-methyl-1, 
4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) in the 
absence of added acid to form a compound of Formula I: 
and 
(b) reacting the compound of Formula I with Ar’BFM in 
the presence of a catalyst to form a compound of Formula III: 
wherein: 
each X is, independently, a ligand, wherein HX, the con 
jugate acid of X, has a pKa of less than or equal to 5: 
Ar" is optionally substituted aryl or heteroaryl, wherein Ar" 
does not have unprotected protic groups; 
Ar’ is an optionally substituted aryl or heteroaryl; 
each R' is, independently, C. alkyl; and 
M is a cation. 
In some embodiments, the process utilizes (1-chlorom 
ethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)bis(tet 
rafluoroborate); and (R')Si X is (CH)-Si-O(C=O) 
CH. 
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In some embodiments, steps (a) and (b) are carried out in a 
single pot. 
In some embodiments, the present application provides 
compounds of Formula II and processes utilizing compounds 
of Formula II (e.g., a process of making a compound of 
Formula I, III, V, VI, or VII), wherein the compounds of 
Formula II are selected from any of the following: 
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wherein Ar is an optionally substituted aryl or heteroaryl, 
wherein Ar does not have unprotected protic groups; and P", 
P', P, P', P, and P are each, independently, protecting 
groups. In some embodiments, each X is acetate. 
35 
In some embodiments, the present application provides a 
compound of Formula I or a process utilizing a compound of 
Formula I (e.g., a process of making a compound of Formula 40 
III, V, VI, or VII starting from a compound of Formula I; or a 
process of making a compound of Formula I), wherein the 
compound of Formula I is selected from any of the following: 
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wherein Ar is an optionally substituted aryl or heteroaryl, 
wherein Ar does not have unprotected protic groups; and P", 
O O P', P, P', P, and P are each, independently, protecting 
N 20 groups; and X is defined above. In some embodiments, each 
N-1SN X is acetate. 
In some embodiments, the present application provides a 
S N compound of Formula III or a process involving a compound 
of Formula III (e.g., a process of making a compound of 
Pl Formula III or a process of making a compound of Formula, 
VI, or VII): 
217 218 
I(X)Ar I(X)Ar 
CN 
OP1 
219 220 
I(X)Ar I(X)Ar 
OP1 
P2 
N1 
P3 
221 222 
I(X)Ar P3 
n 
PIO 
OP2 
223 224 
  








US 9.278,959 B2 
72 
-continued 
71 
O O 
N-1a I(X)Ar 
es 
Pl 
wherein Ar is an optionally substituted aryl or heteroaryl, 
wherein Ar does not have unprotected protic groups; and P", 
P', P, P', P, and P are each, independently, protecting 
groups; and Art and X are defined above. In some embodi 
ments, each X is acetate. In some embodiments, Ar is 
p-methoxyphenyl. In some embodiments, the present appli 
cation provides the compound of Formula V corresponding to 
compounds 217-324, wherein X is replaced by Y. In some 
embodiments, Y is PF - or triflate. 
In some embodiments, the present application provides 
any of the individual compounds 1-324 disclosed herein. In 
Some embodiments, the present application provides any pro 
cess described herein utilizing any of compounds 1-324. In 
Some embodiments, the present application provides a com 
pound of Formula VI or VII, or a salt thereof, derived from 
compounds 217-324. In some embodiments, the compound 
of Formula VI or VII, or salt thereof, derived from compounds 
217-324 has a fluoro atom (e.g. a 'Fatom) at the position 
corresponding to W or Fin Formulas VI and VII, respectively. 
The compounds of Formula III or V can be used to make 
fluorinated compounds, including F labeled compounds as 
described in in US 2011/0313170 and US 2012/0004417, 
which are incorporated herein by reference in its entirety. 
For example, the compounds of Formula III or V can be 
utilized to prepare compounds of Formula VI: 
Ar' W VI 
or a salt thereof, wherein Ar' is as defined above; and W is a 
moiety wherein the pKa of the acid H W is less than 12. In 
one embodiment, the method includes reacting in a polar 
solvent a compound MW, wherein M is a counter ion and W 
is as defined in Formula VI and a compound of Formula V: 
e 
GE) I 
A11 NA2 
wherein Ar' and Ari are as defined above. Y is a leaving 
group; and 
W is as defined above. 
The polar solvent can then be removed from the reaction 
mixture. The remaining mixture can then be combined with a 
nonpolar solvent and heated to produce a compound of For 
mula VI. 
In some embodiments, the method can include heating a 
mixture comprising a nonpolar solvent, a compound MW. 
and a compound of Formula V. 
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In some embodiments, the nonpolar Solution of the reac 
tion mixture of MW and a compound of Formula V can be 
filtered prior to heating. The filtration step can remove any 
insoluble material (e.g., insoluble salts) that remain in the 
reaction mixture. In some embodiments, the solvent can be 
removed from the filtrate prior to heating (i.e., the residue can 
be heated neat). 
In further embodiments, the nonpolar solution of the reac 
tion mixture of MW and a compound of Formula V can be 
filtered prior to heating, the nonpolar solvent can be removed 
(e.g., by evaporation), and the heating of the sample can be 
performed in a different solvent. 
In some embodiments, contaminant salts are removed from 
the solution of the reaction mixture of MW and a compound 
of Formula V in the polar or nonpolar solution by chroma 
tography. For example, the contaminant salts can be removed 
by size exclusion, gel filtration, reverse phase, or other chro 
matographic method prior to heating. 
Substituted aryls and heteroaryls which are prepared using 
the methods described herein can have an W moiety which 
includes any moiety in which the pKa of H W (i.e., the 
conjugate acid of X) is less than about 12. In some cases, W 
is a radioactive isotope (e.g., 'F, 'I, I, and compounds 
having P and P). In some embodiments, W can be chosen 
from halide, aryl carboxylate, alkyl carboxylate, phosphate, 
phosphonate, phosphonite, azide, thiocyanate, cyanate, phe 
noxide, triflate, trifluoroethoxide, thiolates, and stabilized 
enolates. For example, W can be fluoride, chloride, bromide, 
iodide, trifluoroacetate, benzoate, and acetate. In some 
embodiments, X is fluoride. In some embodiments, is a radio 
active isotope of fluoride (e.g., 'F). 
Y can be any suitable leaving group. In some embodi 
ments, Y is a weakly coordinating anion (i.e., an anion that 
coordinates only weakly with iodine). For example, Y can be 
the conjugate base of a strong acid, for example, any anion for 
which the pKa of the conjugate acid (H Y) is less than about 
1. For example, Y can be triflate, mesylate, nonaflate, 
hexaflate, toluene Sulfonate (tosylate), nitrophenyl Sulfonate (nosylate), bromophenyl Sulfonate (brosylate), perfluoro 
alkyl Sulfonate (e.g., perfluoro Co alkyl Sulfonate), tet 
raphenylborate, hexafluorophosphate, trifluoroacetate, per 
fluoroalkylcarboxylate, tetrafluoroborate, perchlorate, 
hexafluorostibate, hexachlorostibate, chloride, bromide, or 
iodide. In some embodiments, a slightly more basic leaving 
group Such as acetate or benzoate may be used. 
The counterion M can be any suitable cation for the desired 
W. The choice of the source of W. and accordingly M, is 
readily within the knowledge of one of ordinary skill in the 
art. For example, M can be chosen from an alkali metal, 
alkaline earth metal and transition metal salts such as, for 
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example, calcium, magnesium, potassium, Sodium and Zinc 
salts. Metal cations may also be complexed to cryptands or 
crown ethers to enhance their solubility and to labilize the W 
moiety. M can also include organic salts made from quater 
nized amines derived from, for example, N.N' dibenzylethyl 
enediamine, chloroprocaine, choline, diethanolamine, ethyl 
enediamine, meglumine (N-methylglucamine) and procaine. 
In some embodiments, M can be a lithium, Sodium, potas 
sium, or cesium with cryptands or crown ethers, a tetrasub 
stituted ammonium cation, or phosphonium cation. When W 
is fluoride, the choice of fluoride source is also readily within 
the knowledge of one of ordinary skill in the art. A variety of 
fluoride sources can be used in the preparation of the fluori 
nated aryl and heteroaryl compounds as provided herein, 
including but not limited to NaF. KF, CSF, tetrabutylammo 
nium fluoride, and tetramethylammonium fluoride. In certain 
instances the choice of fluoride source will depend on the 
functionality present on the compound of Formula V. 
The methods described above can be useful in the prepa 
ration of fluorinated aryl and heteroaryl ring systems. For 
example, the methods can be used to prepare a compound of 
Formula VII: 
Ar F VII 
or a salt thereof, wherein Ar' is an aryl or heteroaryl ring 
system. In particular, the methods can be used to prepare 
radiolabeled fluorinated aryl and heteroaryl ring systems 
(e.g., PET radiotracers). In some embodiments, said F is F. 
In some embodiments, the method can include reacting in a 
polar solvent a compound MF and a compound of Formula V. 
The polar solvent can then be removed from the reaction 
mixture. The remaining mixture can then be combined with a 
nonpolar solvent and heated to produce a compound of For 
mula VII. 
In some embodiments, the method can include heating a 
mixture comprising a nonpolar solvent, a compound MF, and 
a compound of Formula V. 
In some embodiments, the nonpolar Solution of the reac 
tion mixture of MF and a compound of Formula V can be 
filtered prior to heating. The filtration step can remove any 
insoluble material (e.g., insoluble salts) that remain in the 
reaction mixture. In some embodiments, the solvent can be 
removed from the filtrate prior to heating (i.e., the residue can 
be heated neat). 
In some embodiments, the nonpolar Solution of the reac 
tion mixture of MF and a compound of Formula V can be 
filtered prior to heating, the nonpolar solvent can be removed 
(e.g., by evaporation), and the heating of the sample can be 
performed in a different solvent. 
In some embodiments, contaminant salts are removed from 
the nonpolar solution of the reaction mixture of MF and a 
compound of Formula V by chromatography. For example, 
the contaminant salts can be removed by size exclusion, gel 
filtration, reverse phase, or other chromatographic method 
prior to heating. 
The therapeutic use of compounds of Formula VI or VII 
with demonstrated pharmacologic activity in amounts which 
are Suitable for modulation of physiologic or pathologic pro 
cesses and which, in proportion to the demonstrated clinical 
benefits, demonstrate acceptable toxicity. In particular, the 
use of F radiofluorinated molecules of Formula VII claimed 
herein as in Vivo medical imaging agents is contemplated for 
the diagnosis of disease, the noninvasive demonstration of 
physiologic or pathologic processes in Vivo, and for the coor 
dinate use of Such in vivo radiopharmaceutical agents with 
structurally analogous nonradioactive molecules to deter 
mine i) the presence of receptors for the therapeutic agent in 
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individual subjects so that those individuals with probable 
response to the therapy can be identified prior to exposure to 
the drug and/or ii) the amount of administered radiopharma 
ceutical agent localized in an intended target So that dosage 
for the nonradioactive analogous therapeutic agent can be 
determined on a patient by patient basis. 
In some embodiments, the compounds are provided as 
pharmaceutically acceptable salts. As used herein, pharma 
ceutically acceptable salts' refers to derivatives of the dis 
closed compounds wherein the parent compound is modified 
by converting an existing acid or base moiety to its salt form. 
Examples of pharmaceutically acceptable salts include, but 
are not limited to, mineral or organic acid salts of basic 
residues such as amines; alkali or organic salts of acidic 
residues such as carboxylic acids; and the like. The pharma 
ceutically acceptable salts of the present application include 
the conventional non-toxic salts of the parent compound 
formed, for example, from non-toxic inorganic or organic 
acids. The pharmaceutically acceptable salts of the present 
application can be synthesized from the parent compound 
which contains a basic or acidic moiety by conventional 
chemical methods. Generally, such salts can be prepared by 
reacting the free acid or base forms of these compounds with 
a stoichiometric amount of the appropriate base or acid in 
water or in an organic solvent, or in a mixture of the two: 
generally, nonaqueous media like ether, ethyl acetate, etha 
nol, isopropanol, or ACN are preferred. Lists of suitable salts 
are found in Remington's Pharmaceutical Sciences, 17" ed., 
Mack Publishing Company, Easton, Pa., 1985, p. 1418 and 
Journal of Pharmaceutical Science, 66, 2 (1977), each of 
which is incorporated herein by reference in its entirety. 
Definitions 
It is appreciated that certain features of the invention, 
which are, for clarity, described in the context of separate 
embodiments, can also be provided in combination in a single 
embodiment. Conversely, various features of the invention 
which are, for brevity, described in the context of a single 
embodiment, can also be provided separately or in any Suit 
able subcombination. 
As used herein, the phrase “optionally substituted” means 
unsubstituted or substituted. As used herein, the term "sub 
stituted” means that a hydrogenatomis removed and replaced 
by a substituent. It is to be understood that substitution at a 
given atom is limited by Valency. Throughout the definitions, 
the term “C” indicates a range which includes the end 
points, wherein in and mare integers and indicate the number 
of carbons. Examples include C. C., and the like. 
The term “n-membered where n is an integer typically 
describes the number of ring-forming atoms in a moiety 
where the number of ring-forming atoms is n. For example, 
piperidinyl is an example of a 6-membered heterocycloalkyl 
ring, pyrazolyl is an example of a 5-membered heteroaryl 
ring, pyridyl is an example of a 6-membered heteroaryl ring, 
and 1.2.3,4-tetrahydro-naphthalene is an example of a 
10-membered cycloalkyl group. 
As used herein, the term "C., alkyl, employed alone or 
in combination with other terms, refers to a saturated hydro 
carbon group that may be straight-chain or branched, having 
in to m carbons. In some embodiments, the alkyl group con 
tains from 1 to 3 carbon atoms. Examples of alkyl moieties 
include, but are not limited to, chemical groups such as 
methyl, ethyl, n-propyl, and isopropyl. 
As used herein, the term "Calkoxy’, employed alone or 
in combination with other terms, refers to a group of formula 
—O-alkyl, wherein the alkyl group has n to m carbons. 
Example alkoxy groups include methoxy, ethoxy, and pro 
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poxy (e.g., n-propoxy and isopropoxy). In some embodi 
ments, the alkyl group has 1 to 3 carbon atoms. 
As used herein, the term “alkylene', employed alone or in 
combination with other terms, refers to a divalent alkyl link 
ing group. Examples of alkylene groups include, but are not 
limited to, ethan-1,2-diyl, propan-1,3-diyl, propan-1,2-diyl. 
butan-1,4-diyl, butan-1,3-diyl, butan-1,2-diyl, 2-methyl-pro 
pan-1,3-diyl, and the like. 
As used herein, “C., alkenyl refers to an alkyl group 
having one or more double carbon-carbon bonds and having 
in to m carbons. In some embodiments, the alkenyl moiety 
contains 2 to 6 or to 2 to 4 carbon atoms. Example alkenyl 
groups include, but are not limited to, ethenyl, n-propenyl, 
isopropenyl. n-butenyl, sec-butenyl, and the like. 
As used herein, “C., alkynyl refers to an alkyl group 
having one or more triple carbon-carbon bonds and having in 
to m carbons. Example alkynyl groups include, but are not 
limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In 
Some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 
4 carbon atoms. 
As used herein, the term "C., alkylamino” refers to a 
group of formula—NH(alkyl), wherein the alkyl group has n 
to m carbonatoms. In some embodiments, the alkyl group has 
1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "di-C-alkylamino” refers to a 
group of formula —N(alkyl), wherein the two alkyl groups 
each has, independently, in to m carbon atoms. In some 
embodiments, each alkyl group independently has 1 to 6 or 1 
to 4 carbon atoms. 
As used herein, the term “C, alkoxycarbonyl refers to a 
group of formula—C(O)O-alkyl, wherein the alkyl group has 
in to m carbon atoms. In some embodiments, the alkyl group 
has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “C, alkylcarbonyl” refers to a 
group of formula—C(O)-alkyl, wherein the alkyl group has 
in to m carbon atoms. In some embodiments, the alkyl group 
has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “C, alkylcarbonylamino” refers 
to a group of formula - NHC(O)-alkyl, wherein the alkyl 
group has n to m carbon atoms. In some embodiments, the 
alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “C, alkylsulfonylamino” refers 
to a group of formula —NHS(O)-alkyl, wherein the alkyl 
group has n to m carbon atoms. In some embodiments, the 
alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "aminosulfonyl', employed alone 
or in combination with other terms, refers to a group of 
formula—S(O)NH2. 
As used herein, the term “C, alkylaminosulfonyl refers 
to a group of formula —S(O)NH(alkyl), wherein the alkyl 
group has n to m carbon atoms. In some embodiments, the 
alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "di(C. alkyl)aminosulfonyl” 
refers to a group of formula—S(O)N(alkyl), wherein each 
alkyl group independently has n to m carbon atoms. In some 
embodiments, each alkyl group has, independently, 1 to 6 or 
1 to 4 carbon atoms. 
As used herein, the term “aminosulfonylamino” refers to a 
group of formula—NHS(O)NH2. 
As used herein, the term "C., alkylaminosulfonylamino” 
refers to a group of formula —NHS(O)NH(alkyl), wherein 
the alkyl group has n to m carbon atoms. In some embodi 
ments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "di(C., alkyl)aminosulfony 
lamino” refers to a group of formula —NHS(O)N(alkyl). 
wherein each alkyl group independently has n to in carbon 
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atoms. In some embodiments, each alkyl group has, indepen 
dently, 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "aminocarbonylamino” refers to a 
group of formula—NHC(O)NH2. 
As used herein, the term "C., alkylaminocarbonylamino' 
refers to a group of formula —NHC(O)NH(alkyl), wherein 
the alkyl group has n to m carbon atoms. In some embodi 
ments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "di(C., alkyl)aminocarbony 
lamino” refers to a group of formula - NHC(O)N(alkyl). 
wherein each alkyl group independently has n to m carbon 
atoms. In some embodiments, each alkyl group has, indepen 
dently, 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “C, alkylcarbamyl” refers to a 
group of formula —C(O)—NH(alkyl), wherein the alkyl 
group has n to m carbon atoms. In some embodiments, the 
alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “di(C-alkyl)carbamyl refers 
to a group of formula C(O)N(alkyl), wherein the two alkyl 
groups each has, independently, intom carbonatoms. In some 
embodiments, each alkyl group independently has 1 to 6 or 1 
to 4 carbon atoms. 
As used herein, the term “C, alkylthio’ refers to a group 
of formula—S-alkyl, 
wherein the alkyl group has n to m carbon atoms. In some 
embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon 
atOmS. 
As used herein, the term “C, alkylsulfinyl" refers to a 
group of formula—S(O)-alkyl, wherein the alkyl group has n 
to m carbonatoms. In some embodiments, the alkyl group has 
1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term "C., alkylsulfonyl refers to a 
group of formula—S(O)-alkyl, wherein the alkyl group has 
in to m carbon atoms. In some embodiments, the alkyl group 
has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “amino” refers to a group of 
formula NH2. 
As used herein, the term "Ce alkyl-O-C alkylene’ 
refers to a group of formula C- alkylene-O-C alkyl. 
As used herein, the term "Calkyl-NR" Calkylene' 
refers to a group of formula C, alkylene-NR" Calkyl. 
As used herein, the term “aryl', employed alone or in 
combination with other terms, refers to a monocyclic or poly 
cyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocar 
bon, such as, but not limited to, phenyl, 1-naphthyl 2-naph 
thyl, anthracenyl, phenanthrenyl, and the like. In some 
embodiments, aryl is Co aryl. In some embodiments, the 
aryl group is a naphthalene ring or phenyl ring. In some 
embodiments, the aryl group is phenyl. 
As used herein, the term “arylalkyl refers to a group of 
formula-alkylene-aryl. In some embodiments, arylalkyl is 
Co aryl-C alkyl. In some embodiments, arylalkyl is Co 
aryl-C alkyl. In some embodiments, arylalkyl is benzyl. 
As used herein, the term “carbamyl refers to a group of 
formula C(O)NH2. 
As used herein, the term “carbonyl', employed alone or in 
combination with other terms, refers to a —C(O)—group. 
As used herein, the term "carboxy' refers to a group of 
formula –C(O)OH. 
As used herein, the term “cycloalkyl, employed alone or 
in combination with other terms, refers to a non-aromatic 
cyclic hydrocarbon moiety, which may optionally contain 
one or more alkenylene groups as part of the ring structure. 
Cycloalkyl groups can include mono- or polycyclic (e.g., 
having 2, 3 or 4 fused, bridged or spiro rings) ring systems. 
Also included in the definition of cycloalkyl are moieties that 
have one or more aromatic rings fused (i.e., having a bond in 
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common with) to the cycloalkyl ring, for example, benzo 
derivatives of cyclopentane, cyclopentene, cyclohexane, and 
the like. One or more ring-forming carbon atoms of a 
cycloalkyl group can be oxidized to form C=O or C=S 
linkages. In some embodiments, cycloalkyl is C. 
cycloalkyl, which is monocyclic or bicyclic. Examplary 
cycloalkyl groups include 1,2,3,4-tetrahydro-naphthalene, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohep 
tyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cyclohep 
tatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the 
like. In some embodiments, the cycloalkyl group is cyclopro 
pyl, cyclobutyl, cyclopentyl, or cyclohexyl. 
As used herein, the term “cycloalkylalkyl refers to a group 
of formula-alkylene cycloalkyl. In some embodiments, 
cycloalkylalkyl is C-2 cycloalkyl-C alkyl, wherein the 
cycloalkyl portion is monocyclic or bicyclic. In some 
embodiments, cycloalkylalkyl is C. cycloalkyl-C alkyl, 
wherein the cycloalkyl portion is monocyclic or bicyclic. 
As used herein, “C., haloalkoxy' refers to a group of 
formula O-haloalkyl having into in carbonatoms. An example 
haloalkoxy group is OCF. In some embodiments, the 
haloalkoxy group is fluorinated only. In some embodiments, 
the alkyl group has 1 to 6 or 1 to 4 carbon atoms. 
As used herein, the term “halo' refers to a halogen atom 
selected from F, Cl, I or Br. 
As used herein, the term “Chaloalkyl, employed alone 
or in combination with other terms, refers to an alkyl group 
having from one halogen atom to 2s +1 halogenatoms which 
may be the same or different, where “s' is the number of 
carbon atoms in the alkyl group, wherein the alkyl group has 
in to m carbon atoms. In some embodiments, the haloalkyl 
group is fluorinated only. In some embodiments, the 
haloalkyl group is fluoromethyl, difluoromethyl, or trifluo 
romethyl. In some embodiments, the haloalkyl group is trif 
luoromethyl. In some embodiments, the alkyl group has 1 to 
6 or 1 to 4 carbon atoms. 
As used herein, the term "heteroaryl', employed alone or in 
combination with other terms, refers to a monocyclic or poly 
cyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocar 
bon moiety, having one or more heteroatom ring members 
selected from nitrogen, Sulfur and oxygen. In some embodi 
ments, heteroaryl is 5- to 10-membered C. heteroaryl, 
which is monocyclic or bicyclic and which has 1, 2, 3, or 4 
heteroatom ring members independently selected from nitro 
gen, Sulfur and oxygen. The heteroaryl may have one or more 
C=O or C=Slinkages. When the heteroaryl group contains 
more than one heteroatom ring member, the heteroatoms may 
be the same or different. Example heteroaryl groups include, 
but are not limited to, pyridine, pyrimidine, pyrazine, 
pyridazine, pyrrole, pyrazole, azolyl, oxazole, thiazole, imi 
dazole, furan, thiophene, quinoline, isoquinoline, indole, 
benzothiophene, benzofuran, benzisoxazole, imidazol-2-b 
thiazole, purine, or the like. 
A five-membered ring heteroaryl is a heteroaryl with a ring 
having five ring atoms wherein one or more (e.g., 1, 2, or 3) 
ring atoms are independently selected from N, O, and S. 
Exemplary five-membered ring heteroaryls are thienyl, furyl, 
pyrrolyl, imidazolyl, thiazolyl, oxazolyl pyrazolyl, isothiaz 
olyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1.2.3-thiadiaz 
olyl, 1.2.3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 
1,2,4-oxadiazolyl, 1.3,4-triazolyl, 1.3,4-thiadiazolyl, and 
1,3,4-oxadiazolyl. 
A six-membered ring heteroaryl is a heteroaryl with a ring 
having six ring atoms wherein one or more (e.g., 1, 2, or 3) 
ring atoms are independently selected from N, O, and S. 
Exemplary six-membered ring heteroaryls are pyridyl, 
pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl. 
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As used herein, the term "heteroarylalkyl refers to a group 
of formula alkylene-heteroaryl. In some embodiments, het 
eroarylalkyl is Co. heteroaryl-C alkyl, wherein the het 
eroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 
heteroatom ring members independently selected from nitro 
gen, Sulfur and oxygen. In some embodiments, heteroaryla 
lkyl is C. heteroaryl-C alkyl, wherein the heteroaryl por 
tion is monocyclic orbicyclic and has 1, 2, 3, or 4 heteroatom 
ring members independently selected from nitrogen, Sulfur 
and oxygen. 
As used herein, the term "heterocycloalkyl, employed 
alone or in combination with other terms, refers to non 
aromatic ring system, which may optionally contain one or 
more alkenylene or alkynylene groups as part of the ring 
structure, and which has at least one heteroatom ring member 
independently selected from nitrogen, Sulfur and oxygen. 
When the heterocycloalkyl groups contains more than one 
heteroatom, the heteroatoms may be the same or different. 
Heterocycloalkyl groups can include mono- or polycyclic 
(e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring 
systems, including spiro systems. Also included in the defi 
nition of heterocycloalkyl are moieties that have one or more 
aromatic rings fused (i.e., having a bond in common with) to 
the non-aromatic ring, for example, 1,2,3,4-tetrahydro 
quinoline and the like. The carbon atoms or heteroatoms in 
the ring(s) of the heterocycloalkyl group can be oxidized to 
form a C=O, C=S, S=O, or S(=O) group (or other oxi 
dized linkage) or a nitrogenatom can be quaternized. In some 
embodiments, heterocycloalkyl is 5- to 10-membered C 
heterocycloalkyl, which is monocyclic or bicyclic and which 
has 1, 2, 3, or 4 heteroatom ring members independently 
selected from nitrogen, sulfur and oxygen. Examples of het 
erocycloalkyl groups include 1.2.3,4-tetrahydro-quinoline, 
aZetidine, azepane, pyrrolidine, piperidine, piperazine, mor 
pholine, thiomorpholine, pyran, and a 2-oxo-1,3-oxazolidine 
r1ng. 
As used herein, the term "heterocycloalkylalkyl refers to 
a group of formula-alkylene-heterocycloalkyl. In some 
embodiments, heterocycloalkylalkyl is Co. heterocy 
cloalkyl-C alkyl, wherein the heterocycloalkyl portion is 
monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring 
members independently selected from nitrogen, Sulfur and 
oxygen. In some embodiments, heterocycloalkylalkyl is Co. 
heterocycloalkyl-C alkyl, wherein the heterocycloalkyl 
portion is monocyclic orbicyclic and has 1, 2, 3, or 4 heteroa 
tom ring members independently selected from nitrogen, Sul 
fur and oxygen. 
The compounds described herein can be asymmetric (e.g., 
having one or more stereocenters). All Stereoisomers, such as 
enantiomers and diastereomers, are intended unless other 
wise indicated. Compounds of the present application that 
contain asymmetrically Substituted carbon atoms can be iso 
lated in optically active or racemic forms. Methods on how to 
prepare optically active forms from optically inactive starting 
materials are known in the art, Such as by resolution of race 
mic mixtures or by Stereoselective synthesis. Many geometric 
isomers of olefins, C=N double bonds, and the like can also 
be present in the compounds described herein, and all Such 
stable isomers are contemplated in the present application. 
Cis and trans geometric isomers of the compounds of the 
present application are described and may be isolated as a 
mixture of isomers or as separated isomeric forms. 
Resolution of racemic mixtures of compounds can be car 
ried out by any of numerous methods known in the art. An 
example method includes fractional recrystallization using a 
chiral resolving acid which is an optically active, salt-forming 
organic acid. Suitable resolving agents for fractional recrys 
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tallization methods are, for example, optically active acids, 
such as the D and L forms of tartaric acid, diacetyltartaric 
acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic 
acid or the various optically active camphorsulfonic acids 
Such as B-camphorsulfonic acid. Other resolving agents Suit 
able for fractional crystallization methods include stereoiso 
merically pure forms of C.-methylbenzylamine (e.g., S and R 
forms, or diastereomerically pure forms), 2-phenylglycinol, 
norephedrine, ephedrine, N-methylephedrine, cyclohexyl 
ethylamine, 1,2-diaminocyclohexane, and the like. 
Resolution of racemic mixtures can also be carried out by 
elution on a column packed with an optically active resolving 
agent (e.g., dinitrobenzoylphenylglycine). Suitable elution 
solvent composition can be determined by one skilled in the 
art. 
Compounds of the invention also include tautomeric 
forms. Tautomeric forms result from the Swapping of a single 
bond with an adjacent double bond together with the con 
comitant migration of a proton. Tautomeric forms include 
prototropic tautomers which are isomeric protonation states 
having the same empirical formula and total charge. Example 
prototropic tautomers include ketone-enol pairs, amide-imi 
dic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, 
enamine-imine pairs, and annular forms where a proton can 
occupy two or more positions of a heterocyclic system, for 
example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4- 
triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. 
Tautomeric forms can be in equilibrium or sterically locked 
into one form by appropriate Substitution. 
Compounds of the invention can also include all isotopes 
of atoms occurring in the intermediates or final compounds. 
Isotopes include those atoms having the same atomic number 
but different mass numbers. For example, isotopes of hydro 
gen include tritium and deuterium. 
The term, "compound as used herein is meant to include 
all stereoisomers, geometric isomers, tautomers, and isotopes 
of the structures depicted. Compounds herein identified by 
name or structure as one particular tautomeric form are 
intended to include other tautomeric forms unless otherwise 
specified. 
The phrase “pharmaceutically acceptable' is employed 
herein to refer to those compounds, materials, compositions, 
and/or dosage forms which are, within the scope of Sound 
medical judgment, Suitable for use in contact with the tissues 
of human beings and animals without excessive toxicity, irri 
tation, allergic response, or other problem or complication, 
commensurate with a reasonable benefit/risk ratio. 
EXAMPLES 
The invention will be described in greater detail by way of 
specific examples. The following examples are offered for 
illustrative purposes, and are not intended to limit the inven 
tion in any manner. Those of skill in the art will readily 
recognize a variety of noncritical parameters which can be 
changed or modified to yield essentially the same results. 
General Procedure for Oxidation of an Iodoarene with 
F-TEDA-BF/TMSOAc 
Under a dry atmosphere of N, 0.5 mmol of the an aryl 
iodide (1-105) was dissolved in 3 mL of dry acetonitrile. 
Trimethylsilyl acetate (165 mg, 1.25 mmol) was added to the 
solution followed by a solution of F-TEDA-BF (220 mg. 
0.65 mmol) in an additional 3 mL of dry acetonitrile. The 
reaction mixture was allowed to stand at room temperature 
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for 3-8 h. Acetonitrile was then removed in vacuo and 3x3 mL 
dichloromethane were used to extract the remaining mixture. 
The combined dichloromethane solutions were washed with 
4x6 mL aqueous acetate buffer (NaOAc: HOAc=0.5 M: 0.5 
M, pH-5) and dried over sodium sulfate. The dichlo 
romethane was removed in vacuo to yield the crude product, 
which was dissolved in 3 mL of dichloromethane and dripped 
into 150 mL pentane to precipitate the aryliodonium diacetate 
products, which were collected by vacuum filtration. 
Example 1 
1-(Diacetoxyiodo)-4-methoxybenzene (1a) 
AcO-I-OAC 
OMe 
(70%) H NMR (CDCN, 400 MHz, 25° C): & 8.055 (d. 
J=9.1 Hz, 2H), 7.053 (d. J=9.1 Hz, 2H), 3.861 (s.3H), 1.905 (s, 6H); 'C NMR (CD.CN, 100 MHz, 259 C.) & 177.73, 
163.73, 138.75, 118.00, 111.97, 56.85, 20.76; HRMS: (HR 
FAB) calcd. for CHNOI"M-2OAc+3-NBA 385.9889 
found 385.9885. This compound has been prepared previ 
ously: Cerioni, G. and G. Uccheddu, “Solution structure of 
bis(acetoxy)iodoarenes as observed by 17O NMR spectros 
copy, Tetrahedron Lett. 2004, 45,505-507. Characterization 
data were consistent with the previous literature. 
Example 2 
3-(Diacetoxyiodo)benzonitrile 
AcO-I-OAc 
CN 
H NMR (CD.CN,400 MHz, 25° C): 88.515 (s, 1H, H2), 
8.406 (d. J–8.1 Hz, 1H, H6), 7.866 (d. J–8.1 Hz, 1H, H4), 
7.711 (t, J=8.1 Hz, 1H, H5), 1954 (s, 6H, (OCOCH)); 'C 
NMR (CDCN, 100 MHz, 25° C) & 178.25 (CO), 140.65 
(C6), 139.69 (C2), 136.88 (C5), 132.95 (C4), 121.84 (C3), 
115.82 (CN), 109.99 (C1); HRMS (HRFAB): calcd. For 
CHNOI M-2Oac+3-NBA+ 380.9736 found 
380.9722. (Kazmierczak, P. and L. Skulski, 'A simple, two 
step conversion of various iodo arenes to (diacetoxyiodo) 
arenes with chromium(VI) oxide as the oxidant'. Synthesis 
1998, 1721-1723): 'H NMR (CDC1, 200 MHz) & 7.61-8.39 
(4H, m, ArH), 2.02 (6H, s, MeCO).) 
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Example 3 
2-2-(Di-tert-butoxycarbonyl)aminoethyl-4,5- 
dimethoxy-2-iodobenzene 
Boc 
MeO 
OMe 
To a solution of N-iodosuccinamide (NIS) (4.95 g, 22 
mmol) in dry acetonitrile (50 mL) was added 2-(3,4- 
dimethoxyphenyl)ethanamine (3.32 mL, 20 mmol) and trif 
luoroacetic acid (3.85 mL, 50 mmol) with stirring. The mix 
ture was stirred at room temperature in a 250 mL round 
bottom flask for two hours. The acetonitrile was removed and 
the remaining Solid was taken up in water. The water Solution 
was treated with Saturated sodium bisulfite aqueous Solution 
until the purple color disappeared. The pH was adjusted to 8 
and the aqueous Solution was extracted with dichloromethane 
(3x50 mL) The organic layers were combined and dried over 
sodium sulfate. The solvent was evaporated to yield 2-(2- 
iodo-4,5-dimethoxyphenyl)ethanamine (4.3 g, 70%). The 
crude product was dried under dynamic vacuum overnight 
and was sufficiently pure for subsequent steps. 
2-(2-iodo-4,5-dimethoxyphenyl)ethanamine (4.3 g) was 
dissolved in a dry acetonitrile (30 mL) solution containing 
BOC anhydride (4.84g, 22 mmol), 4-dimethylpyridine (195 
mg, 1.6 mmol), and triethylamine (3.1 mL, 22 mmol). The 
reaction was stirred overnight at room temperature before 
being concentrated under reduced pressure. The concentrate 
was diluted with 30 mL ethyl acetate and washed with satu 
rated NHCl solution, water, and brine. The organic layer was 
dried over sodium sulfate and concentrated under reduced 
pressure. The crude product was purified by column chroma 
tography (60 Asilica, 20% ethyl acetate in hexanes, R-03) 
before subjected to a second round of BOC protection. The 
purified, BOC-protected 2-(2-iodo-4,5-dimethoxyphenyl) 
ethanamine was dissolved in 30 mL of anacetonitrile solution 
containing BOC anhydride (4.36 g. 20 mmol), DMAP (195 
mg, 1.6 mmol), and triethylamine (2.78 mL. 20 mmol) and 
stirred at room temperature for 20h. The reaction mixture was 
concentrated in vacuo, diluted with 30 mL ethyl acetate and 
washed with saturated NHCl solution, water, and brine. The 
organic layer was dried over sodium sulfate and concentrated 
under reduced pressure. The crude product was purified by 
column chromatography (60 A silica, 15% ethyl acetate in 
hexanes, R, 0.3) to yield 8.8 g (90%) 2-[2-(di-tert-butoxy 
carbonyl)aminoethyl-4,5-dimethoxy-2-iodobenzene. H 
NMR (CDCN, 400 MHz, 25° C.): 8 7.25 (s, 1H), 6.72 (s, 
1H), 3.77 (t, J=6.60 Hz, 1H), 3.76 (s.3H), 3.74 (s.3H), 2.93 
(t, J=6.60 Hz, 1H), 1.41 (s, 18H); C NMR (CDCN, 400 
MHz, 25° C): & 170.9, 153.3, 150.6, 149.6, 135.3, 122.9, 
114.7,88.9, 82.8, 56.8, 56.4, 47.0, 40. 1, 28.3; HRMS (HREI): 
calcd. for CHINOM" 507. 1118 found 507.1122; calcd. 
for CHINO IM+Na" 530.1016 found 530.1036. 
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Example 4 
2-(2S)-2-(Di-tert-butoxycarbonyl)amino-3-meth 
oxy-3-oxopropyl-4,5-dimethoxy-2-iodobenzene 
MeO 
To a solution of N-iodosuccinamide (8.3g, 37 mmol) in 80 
mL of dry acetonitrile were added (S)-3-(3,4-dimethoxyphe 
nyl)1-methoxy-1-oxopropan-2-amine hydrochloride (4.63 g, 
16.8 mmol) and trifluoroacetic acid (2.7 mL, 37 mmol) with 
stirring. The reaction mixture was stirred at room temperature 
in a 250 mL round bottom flask protected from light for 2 and 
half hours. The acetonitrile was removed and the remaining 
solid was taken up into water. The water solution was treated 
with saturated sodium bisulfite aqueous solution until the 
purple color disappeared. The pH was adjusted to 8 using 
saturated sodium bicarbonate Solution. The neutralized aque 
ous solution was extracted with dichloromethane (3x50 mL) 
The organic layers were combined and dried over sodium 
sulfate. The solvent was evaporated to yield (S)-3-(2-Iodo-4, 
5-dimethoxyphenyl)-1-methoxy-1-oxopropan-2-amine 
(5.17 g., 98%) as a pale yellow oil. The crude product was 
dried over dynamic vacuum overnight and was Sufficiently 
pure for Subsequent steps. 
(5)-3-(2-Iodo-4,5-dimethoxyphenyl)-1-methoxy-1-oxo 
propan-2-amine (5.17 g) was dissolved in a dry acetonitrile 
(40 mL) solution containing BOC anhydride (7.17 g. 32.9 
mmol) and 4-dimethylpyridine (320 mg, 2.63 mmol), triethy 
lamine (4.57 mL, 32.9 mmol). The reaction was stirred over 
night at room temperature before being concentrated under 
reduced pressure. The concentrate was diluted with 40 mL 
ethyl acetate and washed with saturated Nff.C1 solution, 
water, and brine. The organic layer was dried over Sodium 
Sulfate and concentrated under reduced pressure. The crude 
product was purified by column chromatography (60 A silica, 
20% ethyl acetate in hexanes, R-0.3) before being subjected 
to a second round of BOC protection. The product was dis 
solved in 40 mL of an acetonitrile solution containing BOC 
anhydride (7.17 g. 32.9 mmol), 4-dimethylpyridine (320 mg. 
2.63 mmol), triethylamine (4.57 mL, 32.9 mmol) and stirred 
at room temperature for 20 h. The reaction mixture was con 
centrated in vacuo, diluted with 40 mL ethyl acetate, and 
washed with saturated NHCl solution, water, and brine. The 
organic layer was dried over Sodium sulfate and concentrated 
under reduced pressure. Chromatographic purification (60 A 
silica, 15% ethyl acetate in hexanes, R, 0.3) afforded 2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-methoxy-3- 
oxopropyl-4,5-dimethoxy-2-iodobenzene (7.63 g, 82%). "H 
NMR (CDC1, 400 MHz, 25° C): 8 7.19 (s, 1H), 6.62 (s, 
1H), 5.13 (dd, J=11.2 Hz, J-4.3 Hz, 1H), 3.77 (s.3H), 3.76 
(s, 3H), 3.74 (s, 3H), 3.44 (dd, J=14.1 Hz, J-4.3 Hz, 1H), 
3.30 (dd, J=14.1 Hz, J-11.2 Hz, 1H), 1.36 (s, 18H); 'C 
NMR (CDC1, 400 MHz, 25° C): & 170.9, 152.3, 149.9, 
149.1, 133.1, 122.3, 114.5, 89.2, 83.4, 58.3, 56.6, 56.2, 52.7, 
40.6, 28.1; HRMS (HRFAB): calcd. for CHINOs 
M565.1173 found 565.1168, calcd. for CHINOs 
M+H" 566.1251 found 566.1230. 
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Example 5 
2-(Diacetoxyiodo)-1-2-(di-tert-butoxycarbonyl) 
aminoethyl-4,5-dimethoxybenzene (5a) 
AcO-I-OAC Boc 
Boc 
MeO 
OMe 
In a Na charged glovebox. 1 mmol (507 mg) of 2-2-(Di 
tert-butoxycarbonyl)aminoethyl-4,5-dimethoxy-2-iodo 
benzene was dissolved in 5 mL dry acetonitrile and trans 
ferred to a 20 mL high density polyethylene vial. 
Trimethylsilyl acetate (330 mg, 2.5 mmol) and a solution of 
F-TEDA-BF (439 mg, 1.30 mmol) in 8 mL dry acetonitrile 
were dropwisely added sequentially. The reaction mixture 
was allowed to stand at room temperature for 8 h. The reac 
tion solution was placed in a 100 mL Schlenk flask, sealed and 
removed from the glove box. Acetonitrile was removed by 
vacuum transfer and the remaining yellow oil was treated 
with 3 aliquots (5 mL each) of dichloromethane and the 
aliquots were decanted off of the colorless precipitated salts 
that remained in the flask. The combined dichloromethane 
extracts were washed (4x15 mL) with aqueous acetate buffer 
(NaOAc: HOAc=0.5 M: 0.5M, pH=5) and dried over sodium 
sulfate. The dichloromethane was removed in vacuo to yield 
a pale yellow oil. Pentane (8 mL) was added to the oil and 
mixture was placed in an ultrasonic bath and Sonicated until 
the salt solidified until. The pentane was decanted away and 
the remaining light yellow solid was dried under dynamic 
vacuum for overnight to yield 381 mg (0.61 mmol. 61%) 
2-(Diacetoxyiodo)-1-2-(di-tert-butoxycarbonyl)amino 
ethyl-4,5-dimethoxybenzene. H NMR (CDCN, 400 MHz, 
25°C.): 8 7.732 (s, 1H), 7.047 (s, 1H), 3.882 (s.3H), 3.848 (t, 
J=7.6 Hz, 2H), 3.830 (s.3H), 3.120 (t, J=7.6 Hz, 2H), 1.899 (s, 6H), 1.451 (s.9H); 'C NMR (CDCN, 100 MHz, 25°C.) 
& 177.6, 153.8, 153.3, 149.8, 136.5, 1216, 115.9, 113.9, 83.1, 
57.1, 56.6, 48.2,39.1, 28.3, 20.6; HRMS: (HRFAB) calcd. for 
CHINO" (M-2OAc+3-NBA". 645.1304 found 
645.1312. 
Example 6 
2-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxycarbo 
nyl)amino-3-methoxy-3-oxopropyl-4,5-dimethoxy 
benzene (6a) 
AcO-I-OAC 
MeO 
In a Na charged glovebox. 1 mmol (565 mg) of 2-(2S)-2- (Di-tert-butoxycarbonyl)aminol-3-methoxy-3-oxopropyl 
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4,5-dimethoxy-2-iodobenzene was dissolved in 5 mL dry 
acetonitrile and transferred to a 20 mL high density polyeth 
ylene vial. Trimethylsilyl acetate (330 mg, 2.5 mmol) and a 
solution of F-TEDA-BF (439 mg, 1.30 mmol) in 8 mL dry 
acetonitrile were dropwisely added sequentially. The reaction 
mixture was allowed to stand at room temperature for 8 h. The 
reaction solution was placed in a 100 mL Schlenk flask, 
sealed and removed from the glove box. Acetonitrile was 
removed by vacuum transfer and the remaining yellow oil 
was treated with 3 aliquotes (5 mL) of dichloromethane and 
the aliquots were decanted off of the colorless precipitated 
salts that remained in the flask. The combined dichlo 
romethane extracts were washed (4x15 mL) with aqueous 
acetate buffer (NaOAc: HOAc=0.5 M: 0.5 M, pH=5) and 
dried over sodium sulfate. The dichloromethane was removed 
in vacuo to yield a pale yellow oil. Pentane (8 mL) was added 
to the oil and mixture was placed in an ultrasonic bath and 
sonicated until the salt solidified until. The pentane was 
decanted away and the remaining light yellow solid was dried 
under dynamic vacuum for overnight to yield 246 mg (0.36 
mmol. 36%) 2-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxy 
carbonyl)amino-3-methoxy-3-oxopropyl-4,5-dimethoxy 
benzene. "H NMR (CDCN, 400 MHz, 25°C.): 8 7.720 (s, 
1H), 7.011 (s, 1H), 5.236 (dd, J=10.4 Hz, J–3.2 Hz, 1H), 
3.864 (s.3H), 3.821 (s.3H), 3.728 (s.3H), 3.676 (dd, J = 14.8 
Hz, J–3.2 Hz, 1H), 3.446 (dd, J=14.8 Hz, J-10.4 Hz, 1H), 
1898 (s, 6H), 1.352 (s, 9H); C NMR (CDCN, 100 MHz, 
25° C.) & 171.3, 153.3, 152.7, 149.9, 134.5, 121.6, 114.3, 
84.2, 60.8, 57.2, 56.6, 53.3, 39.5, 28.1, 20.5; HRMS: (HR 
FAB) calcd. for CHINO" M-2OAc+3-NBA." 
703,1358 found 703,1365, 
Example 7 
2-2-(Di-tert-butoxycarbonyl)aminoethyl-4,5- 
dimethoxyphenyl-(4-methoxyphenyl)iodonium 
triflate 
Boc Boc 
OTf 
In a N. charged glove box, 381 mg (0.61 mmol) 2-(diac 
etoxyiodo)-1-2-(di-tert-butoxycarbonyl)aminoethyl-4,5- 
dimethoxybenzene was dissolved in 2 mL dry acetonitrile. A 
saturated solution of potassium (4-methoxylphenyl)trifluo 
roborate (130 mg 0.61 mmol) in 5 mL dry acetonitrile was 
added to the reaction mixture followed by trimethylsilyl tri 
fluoroacetate (113 mg 0.61 mmol) solution in 2.5 mL dry 
acetonitrile. Acetonitrile was then removed in vacuo and 
dichloromethane (3x4 mL) were used to extract the remain 
ing yellow oil. The combined dichloromethane solutions 
were washed (3x10 mL) with aqueous acetate buffer 
(NaOAc: HOAc=0.5M: 0.5M, pH=5) and dried over sodium 
sulfate. Dichloromethane was removed in vacuo to yield a 
pale yellow oil. The oil was dissolved in 2 mL dry acetonitrile 
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and poured into a 4 mL aqueous Solution of sodium hexafluo 
rophosphate (587 mg, 3.5 mmol) precipitating the diaryliodo 
nium hexafluorophosphate salt. The mixture was extracted 
with dichloromethane (3x5 mL) and the combined organic 
layers were dried over sodium sulfate, and the solvent was 
removed under reduced pressure. The crude product was puri 
fied by column chromatography (60 A silica, 40% acetone in 
hexanes, R, 0.3) to yield 250 mg (2-[2-(Di-tert-butoxycar 
bonyl)aminoethyl-4,5-dimethoxyphenyl-(4-methoxyphe 
nyl)iodonium hexafluorophosphate (250 mg, 0.33 mmol). 
This compound was dissolved in 1 mL acetonitrile/water (9:1 
by volume) solution and slowly passed down an Amberlite 
IRA-400 ion exchange column (triflate counterion). (The col 
umn was prepared for ion exchange by treating the commer 
cially obtained Amberlite IRA-400 (Cl) resin with saturated 
sodium triflate solution and washing with 10 column volumes 
of distilled water.) 2-2-(Di-tert-butoxycarbonyl)amino 
ethyl-4,5-dimethoxyphenyl-(4-methoxyphenyl)iodonium 
triflate (250 mg, 0.33 mmol) was collected and dried under 
dynamic vacuum for 20 h. The salt was dissolved dichlo 
romethane (2 mL) and transferred to a 20 mL borosilicate 
glass vial. Pentane (18 mL) was carefully layered on top of the 
previous dichloromethane Solution. The vial was capped and 
the sealed container was shielded from ambient light with 
aluminum foil. Colorless needles formed at the solution inter 
face; these were collected after 20 h. The needles were sub jected to a second round of recrystallization using the identi 
cal conditions (dichloromethane (2 mL), pentane (18 mL) 
layering, 20h in dark) to yield colorless needles of 2-2-(di 
tert-butoxycarbonyl)aminoethyl-4,5-dimethoxyphenyl 
(4-methoxyphenyl)iodonium triflate (180 mg, 0.24 mmol). 
The crystals were dried under vacuum and stored in a -40°C. 
freezer under N. "H NMR (CDCN, 400 MHz, 25° C.): 8 
8.01 (d. J=9.01 Hz, 2H), 7.56 (s, 1H), 7.04 (d.J=9.01 Hz, 2H), 
6.95 (s, 1H), 3.84 (s, 3H), 3.83 (s.3H), 3.82 (s.3H), 3.80 (t, 
J=7.16 Hz, 2H), 3.10 (t, J=7.16 Hz, 2H), 1.44 (s, 18H); 'C 
NMR (CDCN, 100 MHz, 25° C.) & 164.3, 1542, 153.8, 
151.0, 138.2, 136.6, 120.3, 119.1, 115.2, 107.0, 83.8, 57.3, 
56.9, 56.8, 47.4, 38.3, 28.3; F NMR (CDCN, 400 MHz, 
25° C): 8 -79.3 (s, 3F). HRMS: (HREI) calcd. for 
C.H.O.NIM-OTf 614.9165. found 614.1627. 
Example 8 
2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-meth 
oxy-3-oxopropyl-4,5-dimethoxyphenyl-(4-meth 
oxyphenyl)iodonium triflate (6b) 
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In a N. charged glove box, 492 mg (0.72 mmol) 2-(diac 
etoxyiodo)-1-(2S)-2-(di-tert-butoxycarbonyl)amino-3- 
methoxy-3-oxopropyl-4,5-dimethoxybenzene was dis 
solved in 2.5 mL dry acetonitrile. A saturated solution of 
potassium (4-methoxylphenyl)trifluoroborate (153.4 mg. 
0.72 mmol) in 6 mL dry acetonitrile was added to the reaction 
mixture followed by trimethylsilyl trifluoroacetate (133.4 
mg, 0.72 mmol) solution in 1 mL dry acetonitrile. Acetonitrile 
was then removed in vacuo and dichloromethane (3x5 mL) 
were used to extract the remaining yellow oil. The combined 
dichloromethane solutions were washed (3x12 mL) with 
aqueous acetate buffer (NaOAc: HOAc=0.5M: 0.5M, pH=5) 
and dried over sodium sulfate. Dichloromethane was 
removed in vacuo to yield a pale yellow oil. Dichloromethane 
was removed in vacuo to yield a pale yellow oil. The oil was 
dissolved in 3 mL dry acetonitrile and poured into a 3 mL 
aqueous solution of Sodium hexafluorophosphate (1 g, 6 
mmol) precipitating the diaryliodonium hexafluorophos 
phate salt. The mixture was extracted with dichloromethane 
(3x6 mL) and the combined organic layers were dried over 
sodium sulfate, and the solvent was removed under reduced 
pressure Minimum amount of ethyl acetate was used to rinse 
off the brown color. Remained oil (200 mg, mmol) was dis 
solved in a mixture of dichloromethane (2.5 mL) and ethyl 
acetate (2.5 mL). This solution was transferred to a 20 mL 
borosilicate glass vial. Pentane (15 mL) was carefully layered 
on top of the previous solution. Colorless needles formed at 
the solution interface; these were collected after 20 h. The 
needles were subjected to a second round of recrystallization 
using the identical conditions (dichloromethane (2.5 mL), 
ethyl acetate (2.5 mL), pentane (15 mL) layering, 20 h in 
dark) to yield colorless needles of 2-(2S)-2-(Di-tert-bu 
toxycarbonyl)amino-3-methoxy-3-oxopropyl-4,5- 
dimethoxyphenyl-(4-methoxyphenyl)iodonium hexafluo 
rophosphate (120mg). This compound was dissolved in 1 mL 
acetonitrile/water (9:1 by volume) solution and slowly passed 
down an Amberlite IRA-400 ion exchange column (triflate 
counterion). (The column was prepared for ion exchange by 
treating the commercially obtained Amberlite IRA-400 (Cl) 
resin with saturated sodim triflate solution and washing with 
10 column volumes of distilled water) 2-(2S)-2-(Di-tert butoxycarbonyl)amino-3-methoxy-3-oxopropyl-4,5- 
dimethoxyphenyl-(4-methoxyphenyl)iodonium triflate 
(120 mg, 0.14 mmol) was collected and dried under dynamic 
vacuum for 20 h. The salt was dissolved in a mixture of 
dichloromethane (3 mL) and ethyl acetate (3 mL) This solu 
tion was transferred to a 50 mL borosilicate glass Schlenk 
tube. Pentane (20 mL) was carefully layered on top of the 
previous dichloromethane solution. The tube was capped and 
the sealed container was shielded from ambient light with 
aluminum foil. Colorless needles foilled at the solution inter 
face; these were collected after 48 h to yield colorless needles 
of 2-(2S)-2-(Di-tert-butoxycarbonyl)amino-3-methoxy 
3-oxopropyl-4,5-dimethoxyphenyl-(4-methoxyphenyl)io 
donium triflate (90 mg 0.11 mmol). The crystals were dried 
under vacuum and stored in a 40° C. freezer under N. "H 
NMR (CDC1, 400 MHz, 25° C.): 8 7.94 (d. J=8.8 Hz, 
H2/H6, 2H), 7.30 (s, H6, 1H), 6.99 (d. J=8.8 Hz, H3/H5', 
2H), 6.93 (s, H3, 1H), 5.10 (dd, J–74 Hz, J-7.3 Hz, CH, 
1H), 3.85 (s, OCH 3H), 3.84 (s, OCH 3H), 3.76 (s, 
–OCH, 3H), 3.74 (s, -COOCH, 3H), 3.62 (dd, J = 14.3 
Hz, J-7.3 Hz, —CH, 1H), 3.39 (dd, J=14.3 Hz, J–7.4 Hz, 
—CH, 1H), 1.44 (s, Boc, 18H); 'C NMR (CDC1, 400 
MHz, 25° C): & 1710 (C–O), 163.7 (C4), 153.5 (C–O), 
152.7 (C4), 150.8 (C5), 137.5 (C2/C6), 134.4(C2), 118.8 
(C6), 118.6 (C3/C5"), 114.6 (C3), 107.6 (C1), 102.7 (C1'), 
84.8 (3° C. on Boc), 58.9 (C-C), 57.1 (4-OCH), 56.6 
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(5-OCH), 56.4 (4'-OCH), 53.4(COOCH), 39.9 (B-C), 28.2 
(1° C. on Boc); 'F NMR (CDCN, 400 MHz, 25° C): 8 
-79.3 (s, 3F); HRMS (HRFAB): calcd. for CHINO 
M-OTf 672.1669, 673. 1703 found. 
Example 9 
2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-meth 
oxy-3-oxopropyl-4,5-dimethoxyphenyl)-4-(3.3- 
dimethylbutoxy)phenyl iodonium hexafluorophos 
phate 
MeO 
(65%). H NMR (CD.CN, 400 MHz, 25° C): & 7.96 (d. 
J=9.1 Hz, 2H), 7.41 (s, 1H), 7.04 (d. J=9.1 Hz, 2H), 6.95 (s, 
1H), 5.09 (dd, J =9.3 Hz, J-5.8 Hz, 1H), 4.10 (t, J–7.2 Hz, 
2H), 3.82 (s.3H), 3.84 (s.3H), 3.76 (s.3H), 3.75 (s.3H), 3.58 
(dd, J=14.7 Hz, J-5.8 Hz, 1H), 3.39 (dd, J=14.7 Hz, J-5.8 
HZ, 1H), 1.70 (t, J–7.2 Hz, 2H), 1.38 (s, 18H), 0.97 (s, 9H): 
'C NMR (CDCN, 100 MHz, 25° C) & 1712, 163.8, 153.9, 
153.2, 151.1, 138.4, 135.0, 119.7, 115.6, 107.4, 102.4, 85.0, 
67.4, 59.3, 57.2, 56.8, 53.5, 42.7, 39.5, 30.4, 29.9, 28.1: 'F 
NMR (CDCN, 400 MHz, 25°C.): 8 -72.9 (d. J=706.2 Hz, 
6F). HRMS: (HREI) calcd. for CHINOPF M-PF+ 
Nat 742.6703 found 742.2457. 
General Procedure for One-Pot Syntheses of Diaryliodonium 
Salts from Aryl Iodides 
In a Na charged glovebox, 0.5 mmol of an aryl iodide was 
dissolved in 3 mL dry acetonitrile. Trimethylsilyl acetate (165 
mg, 1.25 mmol) was added to the solution followed by a 
solution of F-TEDA-BF (220 mg, 0.65 mmol) in 3 mL dry 
acetonitrile. The reaction mixture was allowed to stand at 
room temperature for 3-8 h. A saturated solution of potassium 
(4-methoxylphenyl)trifluoroborate (117.2 mg, 0.55 mmol) in 
6 mL dry acetonitrile was added to the reaction mixture. 
Acetonitrile was then removed in vacuo and 3x3 mL dichlo 
romethane were used to extract the remaining yellow oil. The 
combined dichloromethane solutions were washed (4x6 mL) 
with aqueous acetate buffer (NaOAc: HOAc=0.5 M: 0.5 M, 
pH-5) and dried over sodium sulfate. The dichloromethane 
was removed in vacuo to yield the crude product, which was 
purified by silica gel chromatography and/or crystallization. 
After recrystallization, the obtained acetate salts were subject 
to ion exchange to either the hexafluorophosphate or triflate 
salts. Typically, the acetate salt was dissolved in minimum 
amount of acetonitrile/water (9:1 by volume) solution and 
slowly passed down an Amberlite IRA-400 ion exchange 
column (triflate or hexafluorophosphates counterion). (The 
column was prepared for ion exchange by treating the com 
mercially obtained Amberlite IRA-400 (Cl) resin with satu 
rated sodium triflate or sodium hexafluorophosphate solution 
and washing with 10 column volumes of distilled water.) The 
triflate or hexafluorophosphates salts were collected and 
dried under dynamic vacuum for 20 h and submitted to 
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recrystallization by layering in mixed solvent systems 
(dichloromethane and pentane or dichloromethane, ethyl 
acetate and pentane). 
Example 10 
Bis(4-methoxyphenyl)iodonium 
hexafluorophosphate 
Recrystallization in a mixture of diethyl ether/dichlo 
romethane gave 391 mg of bis(4-methoxyphenyl)iodonium 
hexafluorophosphate (80.5%). H NMR (CDCN, 400 MHz, 
25° C): 87.973 (d. J=9.1 Hz, 4H, H2/H2/H6/H6), 7.046 (d. 
J=9.1 Hz, 4 H., H3/H3/H5/H5), 3.833 (s, 6 H, OMe); 'C 
NMR (CD.CN, 100 MHz, 25°C.) & 164.61 (C4/C4), 138.55 
(C2/C2/C6/C6), 119.42 (C3/C3/C5/C5"), 103.36 (C1/C1'), 
57.06 (OMe); 'F NMR (CDCN, 376 MHz, 259 C.) 
8 -72.833 (d. 1.JP-F=707.3 Hz, PF ); HRMS (HRFAB): 
calcd. for CHOIM-PF)+ 341.0038 found 341.0036. 
Example 11 
(3,4-Dimethoxyphenyl)(4'-methoxyphenyl)iodonium 
hexafluorophosphate 
/ 
Y, e KX 
e PF6 
Recrystallization with diethyl ether/dichloromethane gave 
370 mg (71.7%) of (3,4-dimethoxyphenyl)(4'-methoxyphe 
nyl)iodonium hexafluorophosphate. "H NMR (CDCN, 400 
MHz, 25° C): 87.986 (d. J=9.1 Hz, 2 H, H2/H6"), 7.647 (dd, 
J1=8.9 Hz, J2–2.2 Hz, 1 H, H6), 7.558 (d. J=2.2 Hz, 1 H, H2), 
7.049 (d. J=9.1 Hz, 2 H., H3/H5'), 7.022 (d. J=8.9 HZ, 1 H, 
H5), 1543.845 (s.3 H, 3-OMe), 3.843 (s.3 H, 4'-OMe), 3.834 (s, 3 H, 4-OMe); 'C NMR (CDCN, 100 MHz, 25° C.) & 
164.58 (C4), 154.62 (C4), 152.50 (C3), 138.49 (C2/C6'), 
130.65 (C6), 119.38 (C2), 119.13 (C3/C5'), 115.52 (C5), 
103.37 (C1), 102.64 (C1'), 57.49 (3-OMe), 57.14 (4'-OMe), 
57.05 (4-OMe); F NMR (CDCN, 376 MHz, 25° C.) 
8 -72.786 (d. 1.JP-F=705.8 Hz, PF ); HRMS (HRFAB): 
calcd. for CHOIM-PF)+371.0144 found 371.0156. 
Example 12 
(2-Methoxyphenyl)(4'-methoxyphenyl)iodonium 
hexafluorophosphate 
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mixture until the vial was full. The vial was sealed and pro 
tected from the light. After 3 days, the crystallized product 
was collected by vacuum filtration to give (2-methoxy-5-(2- (4-methoxyphenyl)propan-2-yl)phenyl)(4-methoxyphenyl) 
iodonium hexafluorophosphate as colorless crystalline 
needles; yield 0.30 g (52%). "H NMR (CDCN)400 MHz & 
1.619 (s, 6H), 83.762 (s.3H), 83.854 (s.3H), 83.920 (s.3H), 
& 6.798 (d. J=8.2 Hz, 2H), & 6.982 (d. J=8.4 Hz, 2H), & 7.095 
(d. J–8.4 Hz, 2H), 8 7.112 (d. J=8.4 Hz, 1H), 87.471 (dd. 
J=8.2 Hz, J-2.8 Hz, 1H), 8 7.620 (d. J=2.8 Hz, 1H), 87.897 
(d. J=8.4 Hz, 2H). 
Example 21 
(N,N-di-(t-butoxycarbonyl)-2-((4.5-dimethoxyphen 
ethylamine dicarbonate)(4-methoxyphenyl)iodonium 
hexafluorophosphate 
MeO N(Boc) 
MeO I GE 
e PF 
o1 
The pasty solid was dissolved in 3 mL dichloromethane 
and 7 mL of hexanes was layered on top, and this mixture was 
sealed in a vial protected from light. After the solid had 
crystallized, it was collected by vacuum filtration to afford (N,N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphethylamine 
dicarbonate)(4-methoxyphenyl)iodonium hexafluorophos 
phate as a white amorphous solid; yield 0.49 g (65.2%) 'H 
NMR (CDCN)400 MHz & 144 (s, 18H), & 3.10 (t, J=7.16 
Hz, 2H), & 3.80 (t, J=7.16 Hz, 2H), & 3.82 (s.3H), & 3.83 (s, 
3H), 83.84 (s.3H), & 6.95 (s, 1H), & 7.04 (d. J=9.01 Hz, 2H), 
& 7.56 (s, 1H), 88.01 (d. J=9.01 Hz, 2H). CNMR (CDCN) 
100 MHz & 28.3, 38.3, 47.4, 56.8, 56.9, 57.3, 83.8, 107.0, 
115.2, 119.1, 120.3, 136.6, 138.2, 1510, 153.8, 154.2, 164.3. 
F NMR (CDCN)400 MHz 8 -72.9 (d. J–707.0 Hz, 6F). 
HRMS: (HREI) calcd. for C.H.O.NIPF M-PF+Na" 
614.9165. found. 
Example 22 
(N,N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphen 
ethylaminedicarbonate)(4-(3,3-dimethylbutoxyphe 
nyl))iodonium hexafluorophosphate 
O N(Boc) 
The pasty solid was recrystallized by dissolving the solid in 
3 mL dichloromethane and layering 7 mL of hexanes and 
sealing the contents in a vial, protected from light. After the 
solid had crystallized, it was collected by vacuum filtration to 
afford (N.N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphen 
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ethylamine dicarbonate)(4-(3.3-dimethylbutoxyphenyl)io 
donium hexafluorophosphate as a white amorphous Solid; 
yield 0.49 g (65.2%) 'H NMR (CDCN)400 MHz & 0.968 (s, 
9H), a 1.440 (s, 18H), & 1.692 (t, J=7.2 Hz, 2H), & 3.100 (t, 
J=7.2 Hz, 2H), a 3.795 (t, J–7.2 Hz, 2H), & 3.815 (s, 3H), 8 
3.843 (s, 3H), a 4.093 (t, J–7.2 Hz, 2H), & 6.954 (s, 1H), 8 
7.024 (d. J=8.4 Hz, 2H), & 7.544 (s, 1H). & 7.990 (d. J=8.4 Hz, 
2H). C NMR (CDCN) 100 MHz & 28.60, 30.23, 30.71, 
38.63, 43.05, 47.72, 57.13, 57.63, 67.61, 84.10, 103.07, 
107.39, 115.45, 119.83, 120.68, 136.84, 138.45, 151.16, 
154.01, 154.39, 163.90. F NMR (CD.CN) 376 MHz 
8-79.36. 
Example 23 
(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-meth 
oxyphenyl)iodonium hexafluorophosphate 
N On 
2 ePF 
N Šs "6 
CN 
The crude filtered product was dissolved in CHCl to 
remove it from the filter and the solvent was evaporated. The 
colorless solid was recrystallized from CHCl2/heptanes to 
give a colorless, crystalline solid. (14.6 mg, 50%). "H NMR 
(300 MHz, CDCN) 8–8.63 (d. 1 H, J=4.8 Hz), 8.49 (d. 1 H, 
J=1.2 Hz), 8.40 (s, 1 H), 8.21 (d. 1 H, J=0.8 Hz), 8.01 (d. 2 H, 
J=9.2 Hz), 7.90 (t, 1 H, J=7.6 Hz), 7.68 (d. 1 H, J=7.6 Hz), 
7.48 (t, 1 H, J=6.2 Hz), 7.10 (d. 2 H, J=9.2 Hz), 3.86 (s.3 H): 
'C NMR (75 MHz, CDCN) &=150.51, 14136, 139.12, 
138.22, 137.92, 136.81, 
127.89, 124.35, 118.44, 117.30, 115.64, 55.84; F NMR 
(282 MHz, CDCN):-72.96 (d. 6F, J-705 Hz); HR-FABMS: 
(M-PF)+ 437.014.9 m/z (calcd for CHINO, 437.0145). 
Example 24 
(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl) 
(4-methoxyphenyl)iodonium hexafluorophosphate 
N On 
2 ePF 
N Šs o 
CN 
The crude product was recrystallized from CH2Cl2/hep 
tanes to give a colorless, crystalline solid (12.5 mg, 50%). "H 
NMR (400 MHz, CDCN): 8–8.47 (s, 1 H), 8.39 (s, 1 H), 8.20 
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(s, 1 H), 8.07 (d. 2 H, J=8.1 Hz), 7.72 (t, 1 H, J=8.0 Hz), 7.44 
(d. 1 H, J=8.0 Hz), 7.29 (d. 1 H, J=8.0 Hz), 
7.10 (d. 2 H, J=9.2 Hz), 3.86 (s, 3 H), 2.52 (s, 3 H). 'C 
NMR (100 MHz, CDCN): 8=163.82, 159.59, 14136, 
140.57, 139.16, 138.29, 137.89, 137.10, 126.78, 125.09, 
124.06, 118.49, 115.66, 112.93, 101.28,93.33, 82.99, 55.85, 
23.46; F (376 MHz, CDCN) &=-72.79 (d. 6F, 703.1 Hz); 
HR-FAB MS: (M-PF)* 451.0299 m/z (calcd for 
CHINO, 451.03). 
Example 25 
4-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxycarbo 
nyl)amino-3-methoxy-3-oxopropylbenzene 
O 
AcO- I 
OAc 
N(Boc) 
In a N. charged glove box, (5)-methyl 2-bis-(tert-butoxy 
carbonyl)amino)-3-(4-iodophenyl)propanoate (6.4 g, 12.6 
mmol) was dissolved in 63 mL of dry, distilled acetonitrile in 
a plastic container. To the same container was then added 
trimethylsilyl acetate (4.2 g, 31.4 mmol) and the reaction 
mixture was stirred. In a separate plastic flask, SelectFluor R 
was dissolved in 103 mL of dry, distilled acetonitrile and the 
Selectfluorr mixture was added dropwise to the phenylala 
nine/trimethylsilyl acetate mixture while stirring, and the 
solution was allowed to stir for 8 hours. After 8 hours, the 
acetonitrile was removed in vacuo to yield a white solid. The 
solid was washed with dichloromethane (3x50 mL) and the 
organic fractions were combined. The organic layer was 
washed with aqueous acetate buffer (4x40 mL) (NaOAc: 
HOAc: 0.5M:0.5M; pH 5), and the organic layer was dried 
over sodium sulfate. The dichloromethane was removed in 
vacuo to give a yellow oil, which was treated with 40 mL of 
pentanes and Subjected to an ultrasonic water bath until the 
salt solidified. The pentane was decanted and the white solid 
was placed under high dynamic vacuum for 5 hours. The 
white solid was then carried forward to the next step without 
other purification. "H NMR (CDCN) 400 MHz & 1.40 (s, 
18H), 8 1.93 (s, 6H), 83.29 (dd, J=11.3 Hz, J-140 Hz, 1H), 
83.48 (dd, J=11.3 Hz, J-140 Hz, 1H),83.75 (s.3H),85.25 
(dd, J=11.3 Hz, J-14.0 Hz, 1H), 87.38 (d. J–8.4 Hz, 2H), 8 
8.07 (d. J=8.4 Hz, 2H). 
Example 26 
4-((2S)-2-(di-tert-butoxycarbonyl)aminol-3-meth 
oxy-3-oxopropylphenyl)-4-(3.3-dimethylbutoxy) 
phenyl iodonium triflate 
N(Boc) 
GOTf 
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In a Na charged glovebox, (S)-methyl 2-bis-(tert-butoxy 
carbonyl)amino)-3-(4-iodophenyl)propanoate)(bis-acetyly 
oxy)-v-iodane (1.0g, 1.6 mmol) was dissolved in 5.6 mL of 
dry, distilled acetonitrile. In a separate flask, potassium 
(4-methoxyphenyl)trifluoroborate (0.34g, 1.6 mmol) was 
dissolved in 13 mL of dry, distilled acetonitrile and was 
subsequently added to the hypervalent iodine solution. Next, 
trimethylsilyl trifluoroacetate (0.29 g, 1.6 mmol) was added 
dropwise to the reaction vial while stirring. After 10 minutes 
at room temperature the solvent was removed in vacuo to 
yield an oil. The oil was dissolved in 20 mL of dichlo 
romethane and the organic layer was washed with aqueous 
acetate buffer (3x12 mL) (NaOAc: HOAc: 0.5M:0.5M; pH 
5). The dichloromethane layer was removed in vacuo to yield 
a light yellow solid. The solid was redissolved in 4 mL of dry 
acetonitrile and an aqueous solution of sodium hexafluoro 
phosphate (1.0 g in 4 mL deionized water) was added to the 
reaction flask and the solution was stirred for 3 minutes. The 
formed residue was extracted with dichloromethane (3x20 
mL), the organic layers combined and over Sodium sulfate, 
and removal of the solvent in vacuo gave a white solid. The 
white solid was redissolved in 3 mL of an acetonitrile/water 
(90:10) solution and passed through an IRA-400 resin previ 
ously loaded with trifluoromethanesulfonate anion with an 
additional 25 mL of acetonitrile/water (90:10). The solvent 
was removed in vacuo to give a colorless oil. "H NMR 
(CDCN)400 MHz & 121 (s, 18H), & 3.21 (dd, J = 11.3 Hz, 
J–14.0 Hz, 1H), & 3.42 (dd, J=11.3 Hz, J-14.0 Hz, 1H), 8 
3.69 (s.3H), 63.83 (s.3H), 65.16 (dd, J-49 Hz, J-10.9 Hz, 
1H), & 7.05 (d. J=8.4 Hz, 2H), 8 7.33 (d. J=8.4 Hz, 2H), 87.96 
(d. J=8.4 Hz, 2H), 88.02 (d. J=8.4 Hz, 2H). 
What is claimed is: 
1. A process for making a compound of Formula I: 
comprising: 
treating a compound of Formula II: 
Ar—I II 
with (A) a tetravalent silicon moiety having at least one X 
group bound to Si, wherein each X is, independently, a 
ligand that is a conjugate base of an acid HX, wherein 
HX has a pKa of less than or equal to 12; and is selected 
from the group consisting of halide, aryl carboxylate, 
alkyl carboxylate, phosphate, phosphonate, phospho 
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi 
olates, and Stabilized enolates; and (B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo2.2.2 
octane) bis(tetrafluoroborate), (1-fluoro -4-methyl-1,4- 
diazoniabicyclo[2.2.2]octane) bis(tetrafluoroborate), or 
an optionally substituted N-fluoropyridinium tetrafluo 
roborate; 
wherein: 
Ar" is selected from the group consisting of: 
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wherein Ar is an optionally substituted aryl or heteroaryl, 
wherein Ardoes not have unprotected protic groups; and 
P', P, P, P', P, and P are each, independently, pro 
tecting groups. 
2. The process of claim 1, wherein the process is carried out 
in the absence of added acid. 
3. The process of claim 1, wherein the process utilizes (1-chloromethyl-4-fluoro -1,4-diazoniabicyclo[2.2.2]oc 
tane) bis(tetrafluoroborate). 
4. The process of claim 1, wherein the process utilizes 
(1-fluoro-4-methyl-1,4-diazoniabicyclo 2.2.2]octane) bis 
(tetrafluoroborate). 
5. The process of claim 1, wherein the process utilizes 
N-fluoro-2,3,4,5,6-pentachloropyridinium tetrafluoroborate. 
6. The process of claim 1, wherein the process utilizes less 
than 2 equivalents of (1-chloromethyl-4-fluoro-1,4-diazoni 
abicyclo[2.2.2]octane) bis(tetrafluoroborate), (1-fluoro-4- 
methyl-1,4-diazoniabicyclo[2.2.2]octane) bis(tetrafluorobo 
rate), or optionally substituted N -fluoropyridinium 
tetrafluoroborate for 1 equivalent of the compound of For 
mula II. 
7. The process of claim 1, wherein the process utilizes less 
than 1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazo 
niabicyclo[2.2.2]octane) bis(tetrafluoroborate), (1-fluoro-4- 
methyl-1,4-diazoniabicyclo[2.2.2]octane) bis(tetrafluorobo 
rate), or optionally substituted N -fluoropyridinium 
tetrafluoroborate for 1 equivalent of the compound of For 
mula II. 
8. The process of claim 1, wherein each X is, indepen 
dently, a ligand that is a conjugate base of an acid HX. 
wherein HX has a pKa of less than or equal to 5. 
9. The process of claim 1, wherein each X is O(C=O)CH. 
10. The process of claim 1, wherein the tetravalent silicon 
moiety is (R'),Si X, wherein each R' is, independently, 
C. alkyl or aryl. 
11. The process of claim 10, wherein each R" is methyl. 
12. The process of claim 10, wherein (R'),Si X is 
(CH)Si X. 
13. The process of claim 10, wherein (R'),Si X is 
(CH),Si-O(C=O)CH. 
14. The process of claim 1, wherein the process utilizes 2 
equivalents or more of the tetravalent silicon moiety for 1 
equivalent of the compound of Formula II. 
15. The process of claim 1, wherein the process utilizes 2.5 
equivalents to 3 equivalents of the tetravalent silicon moiety 
for 1 equivalent of the compound of Formula II. 
16. The process of claim 15, wherein the tetravalent silicon 
moiety is (R'),Si X, wherein each R' is, independently, 
C. alkyl or aryl. 
17. The process of claim 1, wherein the processes com 
prises treating a compound of Formula II with (CH)-Si-O 
US 9.278,959 B2 
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(C—)CH; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy 
clo2.2.2]octane) bis(tetrafluoroborate). 
18. The process of claim 1, wherein the processes com 
prises treating a compound of Formula II with 2.5 equivalents 
to 3 equivalents of (CH),Si-O(C=O)CH; and less than 
1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabi 
cyclo[2.2.2]octane) bis(tetrafluoroborate). 
19. A process for making a compound of Formula III: 
III 
Xe 
e 
A11 NA2 
wherein Ar’ is an optionally substituted aryl or heteroaryl, 
the process comprising: 
treating a compound of Formula II: 
Ar—I II 
with (A) a tetravalent silicon moiety having at least one X 
group bound to Si, wherein each X is, independently, a 
ligand that is a conjugate base of an acid HX, wherein 
HX has a pKa of less than or equal to 12; and is selected 
from the group consisting of halide, aryl carboxylate, 
alkyl carboxylate, phosphate, phosphonate, phospho 
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi 
olates, and Stabilized enolates; and (B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2 
octane) bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4- 
diazoniabicyclo[2.2.2]octane) bis(tetrafluoroborate), or 
an optionally substituted N-fluoropyridinium tetrafluo 
roborate; 
wherein: 
Ar' is selected from the group consisting of: 
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wherein Ar is an optionally substituted aryl or heteroaryl, 
wherein Ardoes not have unprotected protic groups; and 
P', P, P, P', P, and P are each, independently, pro 
tecting groups; 
to prepare a compound of Formula I: 
and 
converting the compound of Formula I into a compound of 
Formula III. 
20. The process of claim 19, wherein said converting com 
prises reacting the compound of Formula I with a compound 
of Formula IV: 
wherein M' is aborate, stannane, silane, or zinc moiety. 
21. The process of claim 20, wherein M' is Sn(R), 
Si(R), B(OR), or BCX),M; wherein: 
each R is, independently, C, alkyl; 
each R' is, independently, Ce alkyl, 
each R is, independently, OH or C. alkoxy; or two R. 
groups, taken together with the oxygen atoms to which 
they are attached and the boron atom to which the oxy 
gen atoms are attached, form a 5- to 6-membered het 
erocyclic ring, which is optionally substituted with 1, 2, 
3, or 4C alkyl groups; 
each X is, independently, halo; and 
M is a counterion. 
22. The process of claim 21, wherein the compound of 
Formula IV is ArBFM. 
23. The process of claim 21, wherein the compound of 
Formula IV is ArBFK. 
24. The process of claim 22, wherein the process is carried 
out in the presence of a catalyst. 
25. The process of claim 24, wherein the catalyst is trim 
ethylsilyl trifluoroacetate. 
26. A process for making a compound of Formula V: 
ye 
o 
A11 NA2 
wherein Y is a counterion that is different than X, the 
process comprising: 
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treating a compound of Formula II: 
Ar—I II 
with (A) a tetravalent silicon moiety having at least one X 
group bound to Si, wherein each X is, independently, a 
ligand that is a conjugate base of an acid HX, wherein 
HX has a pKa of less than or equal to 12; and is selected 
from the group consisting of halide, aryl carboxylate, 
alkyl carboxylate, phosphate, phosphonate, phospho 
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi 
olates, and Stabilized enolates; and (B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo2.2.2 
octane) bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4- 
diazoniabicyclo 2.2.2octane) bis(tetrafluoroborate), or 
an optionally substituted N-fluoropyridinium tetrafluo 
roborate; 
wherein: 
Ar' is selected from the group consisting of: 
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108 
I 
5 -IX): 
O O 
N-1N I, converting the compound of Formula I into a compound of 
Formula III; and 
Subjecting the compound of Formula III to ion-exchange in 
S order to form a compound of Formula V. 
Pl 15 27. The process of claim 26, wherein Y is PF or triflate. 
28. The process of claim 26, wherein said ion-exchange 
comprises treating the compound of Formula III with an 
wherein Ardoes not have unprotected protic groups; and aqueous solution of hexaflurophosphate ion, wherein Y is 
P', P, P, P', P, and P are each, independently, pro- PF. 
tecting groups; :k k < k 
wherein Aris an optionally substituted aryl or heteroaryl, 
